




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : G01N 33/58, 33/533, 33/543		A1	(11) International Publication Number: WO 00/58731
			(43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: PCT/US00/06864 (22) International Filing Date: 15 March 2000 (15.03.00) (30) Priority Data: 09/281,512 30 March 1999 (30.03.99) US (71) Applicant: COULTER INTERNATIONAL CORP. [US/US]; 11800 SW 147 Avenue, Mail Code 32-A02, Miami, FL 33196 (US). (72) Inventors: SIIMAN, Olavi; 15920 Cobblestone Court, Davie, FL 33331 (US). MATIJEVIC, Egon; 94 Market Street, Potsdam, NY 13676 (US). SONDI, Ivan; 16 Garden Street, Potsdam, NY 13676 (US). (74) Agent: ALTER, Mitchell, E.; Coulter International Corp., Mail Code 32-A02, P.O. Box 169015, Miami, FL 33116-9015 (US).		(81) Designated States: JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>	

(54) Title: NOVEL SEMICONDUCTOR NANOPARTICLES FOR ANALYSIS OF BLOOD CELL POPULATIONS

(57) Abstract

A semiconductor nanoparticle for use in analysis of biological samples is described. This semiconductor nanoparticle is composed of an aminodextran which is bound to at least one nanoparticle of the formula $(X Y)_n$ wherein X is selected from the group comprising Cd^{2+} , Hg^{2+} , and Zn^{2+} and combinations thereof; and Y is selected from the group comprising S^{2-} , Se^{2-} and Te^{2-} and combinations thereof; and n = approximately 50 to 1000. Also provided are methods of making these semiconductor nanoparticles and methods of making conjugates composed of these semiconductor nanoparticles linked to ligands. Also described are uses for the conjugates in a variety of biological assays.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NOVEL SEMICONDUCTOR NANOPARTICLES FOR ANALYSIS OF BLOOD CELL POPULATIONS

Technical Field

5 The invention relates generally to methods of making semiconductor nanoparticle compounds useful in the analysis of blood cell populations, and particularly to compounds which contain amino-derivatized polysaccharides.

Background Art

10 Multiplex labeling of cells for analysis of biological samples, e.g., mixed cell populations, has been described. However, known methods have limitations which are dictated by the finite number of fluorescence emission colors of known organic fluorophores which can be squeezed into the visible, near-ultraviolet (UV), near-infrared (IR) spectral regions in which conventional measurements are made, e.g., by flow cytometry. These
15 limitations include the widths of emission bands, the spectral overlap between these emission bands, and the excitation wavelength requirements.

 Two examples of labels for cells are CdSe core nanoparticles which have been used for biological staining and observation with a fluorescence microscope [Bruchez J.M. et al., *Science* 281, 2013 (1998) and Chan, W.C.W. and Nie, S., *Science* 281, 2016 (1998)].

20 As the upper limit in the number of usable colors was reached, other methods, based on fluorescence intensity differences have been developed. For example, mutually exclusive pairs of targeted white blood cell populations with widely different, intrinsic numbers of receptors per cell can be labeled by a single color marker and analyzed by flow cytometry [US Patent 5,538,855].

25 Several non-radioactive gene probes, oligos with attached fluorescent dye that hybridize or bind to sample DNA have been described [L.M. Smith et al., *Nature*, 321:674-679 (1986) and L.M. Smith et al, *Nucl. Acids Res.*, 13:2399-2412 (1985)] and are being used for labeling of biological samples. Automated DNA sequencers use four fluorescent dyes with non-overlapping emission bands, one per nucleotide base. However, electrophoretic
30 mobilities of the fluorescent dye-oligo primer conjugates need to be similar for all four conjugates. Also the molecular weight of the conjugates cannot be too high, otherwise they will not move through the polyacrylamide or agarose gel used in the electrophoresis.

 The need for increased sensitivity of probes used in automated analysis by attaching multiple marker molecules per oligonucleotide primer were recognized as early as 1986 [L.
35 M. Smith et al, cited above]. However, only a limited degree of fluorescence enhancement

has been possible for dye-oligo conjugates that are constrained to low molecular weight for separation by gel electrophoresis.

Aminodextrans have been used as reducing and/or protective agents in the preparation or coating of monodispersed colloidal dispersions of magnetic ferrite [U.S. Patent 5,240,640], metal [U.S. Patent 5,248,772], polystyrene [U.S. Patent 5,466,609; US Patent 5,707,877; U.S. Patent 5,639,620; US Patent 5,776,706], and polystyrene-metal [U.S. Patent 5,552,086; U.S. Patent 5,527,713] particles. Aminodextran of sufficiently large molecular weight can accommodate multiple protein molecules. Complexes containing such aminodextrans conjugated to a ligand and a selected fluorescent marker or label have been described. [See, Smith, C., et al, "Detection of Low-Density Surface Markers Using Novel Amplified Fluorochrome-Conjugated Antibodies", Cytometry, Suppl. 9, p. 56, presented at XIX Congress of International Society for Analytical Cytology, March 3-7, 1998; R. Mylvaganam, et al., "Seven Markers, Four Colors, Single Laser Flow Cytometry Using Amplified Fluorochrome Conjugated Antibodies", Cytometry, Suppl. 9, p. 117 (1998), as presented at XIX Congress of International Society for Analytical Cytology, March 3-7, 1998.] However, there continues to be a need for probes which permit increased assay sensitivity, by providing narrower fluorescence bandwidths and enhanced intensities, decreased probe size and increased probe stability.

SUMMARY OF THE INVENTION

The present invention advantageously provides particles which are of a smaller size than previously described labeled aminodextran complexes. The nanoparticles of the invention are further coated with an aminodextran of high degree of substitution to provide higher luminescence intensity than was previously possible in a single small particle.

Thus, in one aspect, the present invention provides a semiconductor nanoparticle for the analysis of fluid samples. The semiconductor nanoparticle contains a water soluble amino derivative of a polysaccharide having a molecular weight from approximately 3,000 to 3,000,000 Da, a size in diameter of less than approximately 150 nanometers, and a degree of substitution of total number of primary and secondary amino groups in the polysaccharide

molecule ranging from 1/150 to 4/1. To form the semiconductor nanoparticle, this aminopolysaccharide is linked to at least one nanoparticle of the formula:



wherein X is selected from the group comprising Cd^{2+} , Hg^{2+} , and Zn^{2+} and combinations thereof; and Y is selected from the group comprising S^{2-} , Se^{2-} and Te^{2-} and combinations thereof; and n = approximately 50 to 1000.

In another aspect, the present invention provides a semiconductor nanoparticle useful for the analysis of biological samples which is bound to an aminodextran having a molecular weight from approximately 3,000 to 500,000 Da, has a size in diameter of 2 to about 10 nanometers, and a degree of substitution of total number of primary and secondary amino groups in the dextran molecule ranging from 1/150 to 4/1. The aminodextran is covalently bound to at least one nanoparticle, which is defined as above.

In yet another aspect, the present invention provides a method of making a semiconductor nanoparticle. This method involves the steps of reacting an amino derivative of a polysaccharide having a molecular weight from approximately 3,000 to 3,000,000 Da with a Periodic Table Group IIB water soluble salt and a Group VIA salt to form a semiconductor nanoparticle. In this method, the semiconductor nanoparticle is a complex of the amino derivative of a polysaccharide and a nanoparticle. The aminopolysaccharide has a diameter of less than approximately 150 nanometers and a degree of substitution of total number of primary and secondary amino groups in the polysaccharide molecule ranging from 1/150 to 4/1. The Group IIB salt having a cation selected from the group consisting of Cd^{2+} , Hg^{2+} , and Zn^{2+} and combinations thereof; and an anion selected from the group consisting of Cl^- , ClO_4^- , NO_3^- and SO_4^{2-} ; said Group VIA water soluble salt having a cation selected from the group consisting of Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Sr^{2+} , and Ba^{2+} and an anion selected from the group consisting of S^{2-} , Se^{2-} and Te^{2-} and combinations thereof; such that the anion selected for the Group IIB salt does not precipitate with the cation of the Group VIA salt. In this method, the presence of the reducing sugar in the polysaccharide retards photo-oxidation of the nanoparticle in the formed polysaccharide semiconductor nanoparticle complex.

In yet a further aspect, the present invention provides a method of making a semiconductor nanoparticle useful in the analysis of biological samples. This method involves mixing an amino derivative of a polysaccharide having a molecular weight from approximately 3,000,000 Da, has a size in diameter of less than approximately 150 nanometers, and a degree of substitution of total number of primary and secondary amino

groups in the polysaccharide molecule ranging from 1/150 to 4/1, a water soluble first salt having a cation selected from the group consisting of Cd^{2+} , Hg^{2+} , and Zn^{2+} and combinations thereof; and an anion selected from the group consisting Cl^- , ClO_4^- , NO_3^- and SO_4^{2-} , and a water soluble second salt having a cation selected from the group consisting of Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Sr^{2+} , and Ba^{2+} and an anion selected from the group consisting of S^{2-} , Se^{2-} and Te^{2-} and combinations thereof; such that the anion selected for the first salt does not precipitate with the cation of the second salt. Upon this mixing step, the first and second salts and the aminopolysaccharide react to form a semiconductor nanoparticle.

In yet a further aspect, the invention provides an aminopolysaccharide-semiconductor nanoparticle complex prepared according to a method of the invention. The semiconductor nanoparticle is a complex of the amino derivative of a polysaccharide and a nanoparticle.

In another aspect, the invention provides a ligand-semiconductor nanoparticle which contains a ligand conjugated to at least one semiconductor nanoparticle.

In still another aspect, the invention provides a method of preparing a ligand-semiconductor nanoparticle. The method involves mixing an amino derivative of a polysaccharide, a water soluble first salt, and a water soluble second salt to form a dispersion containing semiconductor nanoparticles. The dispersion is then purified to remove free salts, and the semiconductor nanoparticle is thereafter activated and purified. A ligand is separately activated and purified. The activated and purified ligand and semiconductor nanoparticle are then mixed, permitting formation of the ligand-semiconductor nanoparticle. The ligand-semiconductor nanoparticle is a conjugate between the selected ligand and the semiconductor nanoparticle.

In yet another aspect, the invention provides a method of detecting a target in a biological sample. The method involves contacting a biological sample suspected of containing a target for a selected ligand with a ligand-semiconductor nanoparticle of the present invention, exciting bound semiconductor nanoparticles to cause them to luminesce; and detecting the luminescence signal, thereby detecting the presence of the target in the sample.

Other aspects and advantages of the invention will be readily apparent from the detailed description of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 provides the Mark-Houwink plot constructed from data for one dextran and ten aminodextran samples as listed in Table 1.

Fig. 2 shows the SDS-PAGE results for various aminodextran lots dissolved in 1xPBS buffer solution: LHS, protocol 1 dissolution; RHS, protocol 2 dissolution. In each set, lanes 1 to 6 from L to R contain 5X-Amdex, lot 1-5; 5X-Amdex, lot 2-2; 5X-Amdex, lot -11; 5X-Amdex, lot 11-6; and 1X-Amdex, lot -75, respectively. The lane containing five narrow bands contains the molecular weight standards.

Fig. 3 provides the absorption spectra of CdS nanoparticles prepared by the controlled double-jet precipitation (CDJP) process using $1 \times 10^{-3} \text{ mol dm}^{-3}(\text{M})$ Na_2S , $1 \times 10^{-3} \text{ mol dm}^{-3}(\text{M})$ (a) CdCl_2 , (b) $\text{Cd}(\text{ClO}_4)_2$, (c) $\text{Cd}(\text{NO}_3)_2$, (d) CdSO_4 solutions, and 5 g dm^{-3} of 5x-aminodextran, lot 11-6.

Fig. 4 provides the absorption spectra of CdS samples collected after 6 s, 30 s, 3 min, and 5 min after the beginning of the CDJP process. The concentrations of CdSO_4 and Na_2S solutions were $1 \times 10^{-3} \text{ mol dm}^{-3}(\text{M})$, and of 5x-aminodextran, lot 11-6, 5 g dm^{-3} .

Fig. 5 provides the absorption spectra of CdS nanoparticles prepared by the CDJP using (a) 1×10^{-3} , (b) 1×10^{-2} , and (c) $1 \times 10^{-1} \text{ mol dm}^{-3}(\text{M})$ CdSO_4 and Na_2S solutions using 5 g dm^{-3} of 5x-aminodextran, lot 11-6 as stabilizer.

Fig. 6 provides the absorption spectra of CdS nanoparticles prepared by the rapid mixing of (a1) 5×10^{-4} and (b1) $5 \times 10^{-3} \text{ mol dm}^{-3}(\text{M})$ CdSO_4 and Na_2S solutions using 5 g dm^{-3} of 5x-aminodextran, lot 11-6 as stabilizer.

Fig. 7 provides the luminescence emission spectra of CdS nanoparticles prepared by the CDJP using $1.3 \times 10^{-3} \text{ mol dm}^{-3}(\text{M})$ of CdCl_2 , $\text{Cd}(\text{ClO}_4)_2$, $\text{Cd}(\text{NO}_3)_2$, and CdSO_4 solutions and $1 \times 10^{-3} \text{ mol dm}^{-3}(\text{M})$ of Na_2S solution. The final concentrations of CdS and 5x-aminodextran, lot 11-6 were $2.5 \times 10^{-4} \text{ mol dm}^{-3}(\text{M})$ and 2.5 g dm^{-3} , respectively.

Fig. 8 illustrates the effect of the pH on the intensity of the luminescence emission of CdS dispersion prepared with CdSO_4 and Na_2S solutions under the same conditions as in Fig. 7.

Fig. 9 provides the absorption spectra of CdS nanoparticles prepared with $3 \times 10^{-3} \text{ mol dm}^{-3}(\text{M})$ $\text{Cd}(\text{ClO}_4)_2$ and $2 \times 10^{-3} \text{ mol dm}^{-3}(\text{M})$ Na_2S solutions using different concentrations of dextran 500, 000 (2, 5, and 20 g dm^{-3}), and 5g dm^{-3} of dextran 20,000.

Fig. 10 provides the absorption spectra of CdS nanoparticles prepared with $3 \times 10^{-3} \text{ mol dm}^{-3}(\text{M})$ $\text{Cd}(\text{ClO}_4)_2$ and $2 \times 10^{-3} \text{ mol dm}^{-3}(\text{M})$ Na_2S solutions using different

concentrations of 1x-aminodextran as a stabilizer: 16 (a), 8 (b), 4 (c), 2 (d), 1 (e), 0.5 (f), 0.2 (g), and 0.05 (h) g dm⁻³.

Fig. 11 provides luminescence spectra of CdS nanoparticles prepared with 3x10⁻³ mol dm⁻³(M) Cd(ClO₄)₂ and 2x10⁻³ mol dm⁻³(M) Na₂S solutions using different concentrations of 1x-aminodextran as a stabilizer: 16 (a), 8 (b), 4 (c), 2 (d), 1 (e), 0.5 (f), and 0.2 (g) g dm⁻³.

Fig. 12 is a plot of the mean diameter of CdS nanoparticles vs. concentrations of 1x-aminodextran and 5x-aminodextran, lot 2-2.

Fig. 13 provides luminescence spectra of CdS nanoparticles prepared with 3x10⁻³ mol dm⁻³(M) Cd(ClO₄)₂ and 2x10⁻³ mol dm⁻³(M) Na₂S solutions using different concentrations of 5x-aminodextran, lot 2-2 as a stabilizer: 16 (a), 8 (b), 4 (c), 2 (d), 1 (e), 0.5 (f), and 0.2 (g) g dm⁻³.

Fig. 14 shows the A₂₈₀ monitor reading versus fraction number chromatogram on Bio-Gel A-5m for T4-5X-Amdex-CdS conjugation mixtures: A, run 7; B, run 9; C, run 10. On the RHS are SDS-PAGE results as follows: A, lane 1, pooled fractions 22-30; lane 2, pooled fractions 31-40; lane 3, purified T4 antibody; standards; B, lanes 1-3, successive fractions of 5X-Amdex-CdS complex purified on Sephadex G-25; lane 4, IT-T4 antibody; lane 5, pooled fractions 31-40; lane 6, standards; C, lane 4, standards; lanes 1, 2, 3, 5, and 6 are pooled fractions 31-35, 36-40, 41-45, 46-50, and 51-55, respectively.

Fig. 15 shows the absorption spectra of T4-5X-Amdex-CdS conjugates in 1xPBS buffer solution: top, run 7, pooled and concentrated fractions 31-40; bottom, run 7, pooled and concentrated fractions 22-30.

Fig. 16 shows the luminescence emission spectra of T4-5X-Amdex-CdS conjugates in 1xPBS buffer solution with 360nm excitation: A, run 7, pooled and concentrated fractions 22-30; B, run 9, pooled and concentrated fractions 31-40; C, run 10, pooled and concentrated fractions 31-45; and D, run 10, pooled and concentrated fractions 36-40.

Fig. 17 shows flow cytometry histograms, cell number (fluorescence events) versus log (fluorescence intensity) for T4-5X-Amdex-CdS conjugate/SAM-PE mixtures with whole blood control, lysed with either digitonin or saponin; and for direct labeling of T4⁺ cells in whole blood control with anti-CD4-FITC fluorescent marker.

Fig. 18 gives a schematic illustration of the formation of T4-5X-Amdex-CdS conjugate and its binding to T4⁺ white blood cells.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides semiconductor nanoparticles which are useful in a variety of applications, but which are particularly well suited for use in biological assays. While previous attempts have been made to utilize amino-derived polysaccharide-particle conjugates for detection of a desired biological target, e.g., a subpopulation of white blood cells, the usefulness of these reagents has been limited to induction of light scattering shifts with relatively large particles. The semiconductor nanoparticles of the invention provide narrow luminescence bandwidths and the possibility of using nanoparticles of the same composition with at least three different sizes, each with different non-overlapping emission bands.

I. SEMICONDUCTOR NANOPARTICLES

The semiconductor nanoparticles of the invention are composed of a water soluble amino derivative of a polysaccharide which is associated with at least one nanoparticle.

As defined herein, a polysaccharide useful in the invention has a molecular weight in the range from about 3,000 to 3,000,000 Da, from about 5000 to about 1,000,000, from about 10,000 to about 500,000, or from about 20,000 to about 250,000. This molecular weight may be readily measured by light scattering or the triple combination of light scattering, viscosity, and refractive index used for aminodextrans (vide infra). Alternatively, other suitable means of determining molecular weight may be size exclusion chromatography or gel electrophoresis. The polysaccharide is also characterized by a size in diameter of about 1 to less than about 150 nanometers (nm) or about 10 to about 100 nm. Currently, a preferred size is in the range of about 10 to about 100 nanometers. In a currently preferred embodiment, the polysaccharide is dextran. However, other suitable polysaccharides may be readily selected by one of skill in the art. For example, such polysaccharides may be natural or synthetic, starches or starch derivatives, cellulose derivatives, amylose and pectin, as well as certain natural gums and derivatives thereof, such as gum arabic and salts of alginic acid.

The polysaccharide selected for use in the present invention is modified so as to contain a degree of substitution of total number of primary and secondary amino groups in the polysaccharide molecule ranging from 1/150 to 4/1 or from 1/25 to 2/5, while retaining water solubility up to at least 100 mg/mL. Unless otherwise noted, as used herein, the degree of substitution is the total number of amino groups (primary and secondary) per monomeric glucose unit in the aminodextran or other aminopolysaccharide molecule. In a currently preferred embodiment the amino derivative of a polysaccharide used in the invention is

aminodextran, most preferably which has been substituted with 1,3-diaminopropane. There are a variety of other aminodextrans which may be obtained from commercial sources or prepared using known techniques. Methods of preparing aminodextrans are described in US Patent 5,466,609 and US Patent 5,527,713 by periodate oxidation of dextran followed by
 5 reaction with 1,3-propanediamine. Of course, the present invention is not limited to these methods of producing aminodextrans. Preferably, the aminodextran is 5X-aminodextran (up to 350,000 Da, degree of substitution 1/5 - 1/8, calculated on basis of primary amines) or 1X-aminodextran (up to 1,000,000 Da, degree of substitution, 1/28 - 1/45, calculated on basis of primary amines). One of skill in the art may readily select other suitable aminodextrans
 10 and/or amino derivatives of polysaccharides for use in the present invention. The aminopolysaccharides are further characterized by having free amine groups which can be activated for linkage to a protein or other ligand.

The selected aminopolysaccharides are thereafter linked to at least one nanoparticle of the formula:

15



wherein X is selected from the group comprising Cd^{2+} , Hg^{2+} , and Zn^{2+} and combinations thereof; and Y is selected from the group comprising S^{2-} , Se^{2-} and Te^{2-} and combinations thereof; and n = approximately 50 to 1000. In a currently preferred embodiment, the nanoparticle is CdS.

20

In the semiconductor nanoparticle of the invention, each aminopolysaccharide may be covalently bound to one or more nanoparticles, and in certain embodiments, as many as several hundred nanoparticles (e.g., about 200) may be covalently bound to the aminopolysaccharide. The presence of luminescence in the resulting semiconductor nanoparticles is believed to be an indication of covalent binding.

25

II. METHOD OF MAKING SEMICONDUCTOR NANOPARTICLES

In another aspect, the present invention provides methods of making the semiconductor nanoparticles of the invention.

30

This method involves reacting an aminopolysaccharide as defined herein, a cation from Group IIB of the Periodic Table selected from among one or more of Cd^{2+} , Hg^{2+} , and Zn^{2+} , and an anion from Group VIA of the Periodic Table selected from among one or more of S^{2-} , Se^{2-} and Te^{2-} .

Suitably, the cation donor is water soluble at room temperature. In a preferred embodiment, the cation donor is a Group IIB salt in which the cation is selected from among

Cd^{2+} , Hg^{2+} , and Zn^{2+} and combinations thereof; and the anion is selected from among Cl^- , ClO_4^- , NO_3^- and SO_4^{2-} . Currently, the preferred cation is Cd^{2+} . Thus, examples of suitable Group IIB salts include CdCl_2 , $\text{Cd}(\text{ClO}_4)_2$, $\text{Cd}(\text{NO}_3)_2$ and CdSO_4 . Suitably, these salts may be in solution, or provided in dry form.

5 Suitably, the anion donor is also water soluble at room temperature. Preferably, the anion donor is a Group VIA salt or salt solution which has a cation selected from among Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Sr^{2+} , and Ba^{2+} and an anion selected from among S^{2-} , Se^{2-} and Te^{2-} and combinations thereof. The Group IIB salt and the Group VIA salt are selected so that the anion of the Group IIB salt does not precipitate with the cation of the Group VIA salt and the
10 cation of the Group VIA salt does not precipitate with hydroxide ion. This determination is well within the skill of those in the art. Currently, the preferred anion is S^{2-} . Thus, examples of suitable Group VIA salts include Li_2S , Na_2S , K_2S , Rb_2S , Cs_2S , SrS , and BaS . Suitably, these salts may be in solution, or provided in dry form.

 Desirably, the aminopolysaccharide is mixed in aqueous media which contain, at a
15 minimum water, with the cation donor and the anion donor. The mixture containing the aminopolysaccharide, the Group IIB cation donor and the Group VIA anion donor are then reacted to form polysaccharide semiconductor nanoparticles.

 In one embodiment, the cation donor (e.g., Group IIB salt) is mixed with the aminopolysaccharide to form a first product and the anion donor (e.g., Group VIA salt) is
20 mixed with the aminopolysaccharide to form a second product. The first product and the second product are then reacted to form the polysaccharide semiconductor complex. Suitably, this occurs in the presence of a high concentration of aminopolysaccharide. The aminopolysaccharide may be added in high concentration before addition of the cation and/or anion donors (e.g., salts). Alternatively, aminopolysaccharide may be added during the
25 mixing process substantially simultaneously with or before addition of the salt(s). As defined herein, "high concentration" of aminopolysaccharide refers to an amount in the range of 0.2 to about 50 mg aminopolysaccharide per ml of reaction mixture, preferably, about 15 mg/ml to about 25 mg/ml, and more preferably about 20 mg/ml aminopolysaccharide/reaction mixture.

30 The Group IIB cation and the Group VIA anion may be added to the water in approximately equivalent amounts (i.e., at a molar ratio of about 1 to about 1). For example, Group IIB salts and Group VIA salts may be added in amounts so that the mixture contains about $1 \times 10^{-4} \text{ mol dm}^{-3}$ to $1 \times 10^{-1} \text{ mol dm}^{-3}$. However, to obtain maximum luminescence emission intensity from the nanoparticles, superior results have been obtained when the

mixture contains an excess of the donated cation from the Group IIB salt, as compared to the concentration of the anion from the Group VIA salt. This excess donated cation may be as much as about 50% higher concentration of the Group IIB salt. However, this is believed to reflect optimization of the present invention and is not essential for production of the semiconductor nanoparticles of the invention.

Suitably, the method of the invention is performed at a relatively high pH, e.g., in the range of about 9 to about 12, and most suitably, in the range of about 10 to 11. Where needed, the pH may be adjusted by addition of a water soluble base, e.g., NaOH, to the reaction mixture. One of skill in the art can readily select other suitable water-soluble bases such as KOH, NaOH, LiOH, RbOH, CsOH, Sr(OH)₂, or Ba(OH)₂ for use in the method of the invention.

In one desirable embodiment, the semiconductor nanoparticles of the invention are prepared by rapid mixing of reactant solutions. Generally, this procedure involves rapidly adding a Group IIB salt solution into a stirred solution of a Group VIA salt containing aminodextran. The mixing of these solutions yields sols of Group IIB cation/Group VIA anion. These sols are then further stirred. The pH is raised with NaOH to about 10 - 11. This rapid mixing invention has been found to yield semiconductor nanoparticles of a consistently smaller size than those produced by other methods.

Alternatively, the semiconductor nanoparticles of the invention may be prepared using a controlled double-jet precipitation process. Generally, this method involves introducing solutions containing the Group IIB salt and the Group VIA salt into a reactor containing stirred aqueous aminopolysaccharide solution. The reactor outer jacket is suitably maintained at a temperature which prevents overheating (e.g., about 25°C). The mixing immediately yields sols, which are further stirred. Suitably, the pH of the prepared semiconductor nanoparticle dispersions is adjusted to a pH of about 10 - 11, and most preferably 10.5. This controlled double-jet precipitation process has been found to yield a more stable dispersion of semiconductor nanoparticles of the invention than when it is prepared by the rapid mixing method, particularly at high concentrations.

Regardless of whether these mixing processes or other mixing processes are selected by one of skill in the art for use in the method of the invention, it has been found that there are sufficient amounts of reducing sugars in the aminopolysaccharide that photo-oxidation of the formed aminopolysaccharide semiconductor nanoparticle is retarded, and no further steps are required to prevent photo-oxidation. Thus, the dispersion resulting from the above-described reaction contains stable, fluorescent, semiconductor nanoparticles.

Suitably, the resulting dispersion of luminescent semiconductor nanoparticles is characterized by an emission spectrum which is dependent upon the elements which form the nanoparticle, the size of the resulting semiconductor nanoparticle, and the concentration of the semiconductor nanoparticle in the dispersion. Suitably, each type of semiconductor nanoparticle, e.g., such as CdS-aminodextran, can provide at least three non-overlapping emission bands, through the use of different nanoparticle sizes between 2 and 10 nm in diameter. For example, CdS dispersions may give luminescence band maxima from 450 nm for low concentrations of aminodextran to 550 nm at the highest concentration. Other types of II-VI semiconductors, either singly or in combination from the following array, may be readily selected for use in the method of the invention.

Matrix of II-VI Semiconductors

	<u>Zn</u> ²⁺	<u>Cd</u> ²⁺	<u>Hg</u> ²⁺
<u>S</u> ²⁻	ZnS	CdS	HgS
<u>Se</u> ²⁻	ZnSe	CdSe	HgSe
<u>Te</u> ²⁻	ZnTe	CdTe	HgTe

Generally, the emission spectra of the II-VI semiconductors which compose these nanoparticles span the range from blue (~450 nm) to red (~900 nm). These spectra can be readily determined by one of skill in the art using conventional methods. Suitably, the semiconductor nanoparticles of the invention may be used singly or in combination as mixed nanoparticles with other types of semiconductors to provide continuous tunability of emission bands from blue to red wavelengths. Selection of the desired nanoparticles, taking into consideration emission spectra, may depend upon the desired use for these semiconductor nanoparticles. Desirably, these semiconductor nanoparticles are purified prior to conjugation with a ligand, as described in detail below, or used in a variety of other applications.

Purification may be performed by any suitable means known in the art. Currently, a particularly desirable method is chromatography, e.g., using a Sephadex or Bio-Gel column. However, other suitable methods of purification such as membrane filtration may be readily selected.

III. A LIGAND-AMINOPOLYSACCHARIDE-SEMICONDUCTOR NANOPARTICLE CONJUGATE

Suitably, the semiconductor nanoparticle-aminopolysaccharide complexes of the invention may be linked to a protein or other ligand for use as markers, in biological assays, and the like.

As defined herein, the term "ligand" refers to a component which preferentially binds to all or a portion of a target peptide or protein. Preferably, this target is a viral or cell surface receptor or other protein and a ligand useful in the invention is an antibody or a functional fragment thereof (i.e., a fragment which binds the same target as the antibody) specific for the target protein. Such antibodies or fragments include polyclonal antibodies from any native source, and native or recombinant monoclonal antibodies of classes IgG, IgM, IgA, IgD, and IgE, hybrid derivatives, and fragments of antibodies including Fab, Fab' and F(ab')₂, humanized or human antibodies, recombinant or synthetic constructs containing the complementarity determining regions of an antibody, and the like. Most preferably, a ligand useful in this invention is capable of binding to a cell surface receptor on a population of white blood cells (WBC). For use in detecting WBC populations, a preferred ligand is an anti-CD4 antibody. The methods useful for construction of all such ligands are known to those of skill in the art. The particular method of making and the type of monoclonal antibody is not limited to such techniques and it is envisioned that any technique for making such antibodies is within the practice of the invention. Similarly, the selection of the ligand or target protein is not a limiting factor in this invention.

IV. A METHOD OF PREPARING A LIGAND-AMINOPOLYSACCHARIDE-SEMICONDUCTOR NANOPARTICLE CONJUGATE

Thus, in another aspect, the present invention provides a method of preparing a ligand-aminopolysaccharide semiconductor nanoparticle conjugate. Suitably, this method involves activating a purified semiconductor nanoparticle-aminodextran complex of the invention using conventional methods. For example, activation may be by addition of sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (sulfo-SMCC) solution in 1xPBS to the dispersion containing the purified semiconductor nanoparticle-aminodextran complex. The activated semiconductor nanoparticle-aminodextran complex is then purified. Suitable purification methods may be readily selected by one of skill in the art. In one example, the mixture containing sulfo-SMCC and semiconductor nanoparticle-aminodextran complex are stirred (e.g., for about one hour at room temperature) and the

reaction mixture chromatographed, e.g., by application of the mixture to a G-50 Sephadex column equilibrated with 1xPBS. A sample may then be eluted using 1xPBS, collected, and absorption determined to confirm activation. Other suitable activation and purification methods may be readily determined and substituted for the above-described method.

5 The selected ligand, i.e., a monoclonal antibody, is also activated. Suitable activation methods may be readily selected by one of skill in the art. An example of such a method involves the addition of a solution of 2-iminothiolane in 1xPBS to antibody concentrate. The resulting solution suitably has an iminothiolane-to-antibody molar activation ratio of about 5-20 and preferably from 10-15 and is mixed at ambient temperature for about one to two
10 hours. The activated antibody is then purified, e.g., by chromatography or another suitable method, and combined with the activated and purified polysaccharide-semiconductor nanoparticle complex.

 Suitably, the dispersion containing the activated, purified ligand and the activated, purified polysaccharide-semiconductor nanoparticle complex or mixtures thereof is stirred for
15 a sufficient time to permit formation of the ligand-polysaccharide- semiconductor nanoparticle conjugate.

 The ratio of ligand to polysaccharide-semiconductor nanoparticle complex in the resulting conjugate will depend upon a number of factors, including the relative sizes of the polysaccharide-semiconductor nanoparticle complex and the ligand. For example, a
20 conjugate of the invention composed of an antibody and an aminodextran-CdS semiconductor particle may contain about 5 to about 8 antibodies to each aminodextran-CdS semiconductor particle. However, other conjugates may contain a ratio of 1 ligand to each semiconductor nanoparticle, or may even contain as many as five polysaccharide-semiconductor nanoparticles to each antibody. Suitably, the number of polysaccharide-semiconductor
25 nanoparticles complexed to the ligand is such that the activity of the ligand is not substantially affected.

 So formed, the conjugates may be used in a wide variety of ways. For example, for enhancing known methodologies for the detection, diagnosis, measurement and study of antigens and other proteins, either present as individual molecules or in more complex
30 organizations, such as viruses, cells, tissue, organelles, e.g., plasmids, nuclei, etc. The conjugates may be used in immunoassays or competitive protein binding assays, where the semiconductor particles serve as fluorescent labels.

V. A METHOD OF DETECTING A TARGET IN A BIOLOGICAL
SAMPLE

According to the present invention, a particularly desirable use of the subject conjugates is labeling (i.e., luminescent staining) of cells. These conjugates may be used as
5 single markers which provide an enhanced signal. In another embodiment the conjugates may be used in combinations, preferably where the luminescence emission maximum of the ligand-aminopolysaccharide-semiconductor nanoparticle conjugates are separated by at least about 50 nm, preferably by at least about 70 nm. Alternatively, the conjugates may be used
10 in conjunction with other protein or non-protein fluorophores, where the emission maxima are separated by at least about 100 nm, preferably about 150 nm.

By using combinations of fluorophores, one can provide for the detection of subsets of aggregations, such as particular types of cells, strains of organisms, strains of viruses, the natural complexing or interaction of different proteins or antigens, etc. In some
15 embodiments, combinations include fluorophores capable of being excited with the same laser light source.

Thus, according to this invention, cell populations may be identified by using one or more of: (a) a semiconductor nanoparticle conjugate of the invention containing a ligand (e.g., an antibody which binds a cell surface antigenic receptor) on a first cell subpopulation; and (b) a second semiconductor nanoparticle conjugate of the invention having a different
20 wavelength of luminescence emission than the first conjugate due to either a sufficiently different nanoparticle size or nanoparticle composition and an antibody specific for a mutually exclusive second cell subpopulation. Optionally, the cell population may be identified using a conventional labeled conjugate in addition to a semiconductor nanoparticle conjugate(s) of the invention. The combination of these labeled, receptor-bound conjugates
25 produces different luminescent-labeled cell populations in mixtures with whole blood with distinct and non-overlapping luminescence band maximum positions. Viruses and other biological targets may be identified using similar techniques.

The conjugates of the invention are particularly well suited for detecting a target in a biological sample. Typically, this involves contacting a biological sample suspected of
30 containing a target for a selected ligand with the ligand-semiconductor nanoparticle conjugate, exciting bound semiconductor nanoparticle conjugate to cause it to luminesce; and detecting the luminescence signal which is indicative of the presence of the target in the sample. This method is particularly well suited to flow cytometry analysis.

However, other methods, including enzyme linked immunosorbent assay (ELISA) may be readily utilized. In ELISA, or another similar method, the biological sample, or the conjugate may be immobilized. Where this is the case, a washing step may be employed to separate the semiconductor nanoparticle conjugate which has bound to the target from unbound semiconductor nanoparticle conjugate.

In one particularly desirable embodiment, the method of the invention is employed to detect multiple subsets of white blood cells. In this application, one to multiple sets of WBC cell populations are provided. For the first population, a first ligand-semiconductor nanoparticle conjugate of the invention is provided, in which the ligand binds to a receptor in the first population. For the second population, a second labeled ligand is provided. The second ligand binds to a second receptor within the population of white blood cells and is provided with a label which is distinguishable (e.g., visually or colorimetrically) from the semiconductor nanoparticle conjugate conjugated to the first ligand. This second ligand may be conjugated to a second semiconductor nanoparticle conjugate or to a conventional label. The cell populations are then incubated with the first and the second labeled ligands for a time sufficient to permit receptor-labeled ligand complexes to form therebetween. Where semiconductor nanoparticles have been utilized as the labels, the luminescence emission intensities may be determined and the populations distinguished by the variations in intensity and color.

Other suitable assays and uses for the semiconductor nanoparticle conjugates of the invention may be readily determined by one of skill in the art.

The following examples are provided to illustrative only and do not limit the scope of the invention. One skilled in the art will appreciate that although specific reagents and conditions are outlined in the following examples, modifications can be made which are meant to be encompassed by the spirit and scope of the invention.

Example 1 - Preparation of aminodextrans

Aminodextran-3M and -3000 were obtained from Molecular Probes, Inc., Eugene, OR. Dextran, amino, nominally of 2,000,000 MW, Cat. No. D-7145, was purchased from Molecular Probes, Inc., Eugene, OR. Analytical data for lot 6551-3: 130 amines/mole. Measurement of the molecular weight of this lot of aminodextran by the Viscotek triple detection system (vide infra) gave ~ 3M Da. Therefore, there are $3,000,000\text{g/mol} \div 162.1\text{g/mol glucose monomer} = 18,507$ glucose units/dextran molecule or $130/18,507 = 0.00702$, i.e. ~1/142 degree of substitution with single amine group per reacted glucose unit.

The degree of substitution unless otherwise noted is defined as the total number of amino groups (primary and secondary) per monomeric glucose unit in the aminodextran molecule. Dextran of different average molecular weights (20,000 Da and 500,000 Da) were obtained from the Fluka Company.

- 5 Dextran, T-2M, for the preparation of aminodextran was obtained from Sigma, as were other chemicals related to their preparation. All inorganic chemicals were of reagent grade and were not further purified.

1. Preparation of 1x-aminodextran and 5x-aminodextran.

- 10 The 1x-aminodextran and 5x-aminodextran lots were prepared as follows. In a standard preparation of 1X-Amdex, 80g of solid dextran were blended in 600mL distilled water to dissolve all the dextran. 8.56g of sodium m-periodate, dissolved in 100mL of distilled water, were added dropwise to the dextran solution over about 10 minutes with vigorous stirring, after which the mixture was stirred at room temperature for an additional 3
15 hours. The resulting viscous reaction mixture was then diluted to 2 liters with distilled water and desalted using a hollow fiber cartridge, A/G Technology Corp. model UFP-5-E-35, 5,000 molecular weight cut-off or model UFP-30-E-35, 30,000 molecular weight cut-off, with tubing adaptor kit, KA12-3P. About 18-22L of distilled water were used to obtain a solution having a final pH of 6.0-6.5. To the final, 800mL volume of washed, oxidized dextran
20 solution were slowly added 80mL of colorless, liquid 1,3-diaminopropane (DAP), over about 10 minutes at room temperature. The resulting mixture was then stirred at room temperature for an additional 3 hours. Then, 3.2g of sodium borohydride dissolved in 40mL of 1mM aqueous sodium hydroxide were added to the room temperature aminodextran reaction mixture over about 5 minutes with stirring. The resulting mixture was stirred for an additional
25 1 hour and then desalted using a hollow fiber cartridge. About 20-25L of distilled water were needed to reduce the specific conductance to about $3-4 \mu\text{mho}\cdot\text{cm}^{-1}$ and the pH to 6.0-6.5. The final volume of aminodextran was 400mL. This solution was passed through a 0.2 μm sterile cellulose acetate filter unit and then freeze-dried over 48 hours in a model TDS-00030-A, Dura-Dry microprocessor-controlled freeze-drier (FTS Systems, Inc.) to obtain 48 grams
30 of flaky, pale yellow crystals, a 52% yield. Elemental analysis are: Obsd.: C, 42.53; H, 6.52; N, 1.01; O (by difference), 49.94. Calculated for $\text{C}_{49}\text{H}_{84}\text{NO}_{40} \cdot 3\text{H}_2\text{O}$: C, 42.61; H, 6.57; N, 1.01; O, 49.81. The empirical formula, $\text{C}_{49}\text{H}_{90}\text{NO}_{43}$, is very similar to the formula based on 31 units of glucose, 1 unit of fully (two) DAP-substituted sugar ring and three units of water. The degree of substitution in dextran by DAP was 1/32. Other runs varied between

1/28 and 1/45 degree of substitution. Similar results were obtained for aminodextrans prepared from dextrans having nominal average molecular weights of 10K to 2M Da with 1X through 5X-diaminopropane substitution. All the aminodextrans were initially prepared according to the above method using 2 to 5 times the amount of sodium periodate used in the 1X oxidation of dextran. The amount of DAP used for Schiff's base formation was kept constant. Modifications were made to periodate oxidation, diamine addition, and borohydride reduction reactions. The first modification was to use only a ten percent (10%) excess of diamine over the stoichiometric 2:1 diamine:periodate molar ratio previously used. Second, the diamine addition reaction was conducted at a temperature in the range of 5-10°C. Third, the diamine addition reaction was spectroscopically monitored in the near ultraviolet (UV) region for Schiff's base formation, which was deemed completed when successive spectral analyses indicated a plateau was reached. The reaction was then stopped. These modifications reduced depolymerization, and thus gave higher yield of product. Elemental analyses for 5X-Amdex, lot -11, which was prepared at a 500g dextran scale were C=44.45%, H=7.20%, N=3.79%, O (by difference) =44.56%. The empirical formula was $C_{13.7}H_{26.4}O_{10.3}N$, which is similar to the formula $C_{13}H_{24}O_9N \cdot H_2O$ based on 5 units of glucose per one unit of 1.5 diaminopropane-substituted sugar ring ($C_{9.5}H_{21}O_2N_3$), or a degree of substitution of DAP in dextran of 1/6. Similar results were obtained for 5X-Amdex, lot -69 prepared at a 300g dextran scale.

20

2. Cross-linked 5X-Aminodextran.

Crosslinked 5X-Amdex was prepared by a modified procedure. T-2M dextran, 500g, 3.08mol, was transferred to a one gallon Waring blender Model CB6 commercial, stainless steel bowl containing 5000mL of distilled water. The mixture was blended at 1/2 maximum speed until all the white solid of dextran was dissolved, typically for about 5 minutes. A solution of 267.5g, 1.25mol, of sodium m-periodate in 2000mL distilled water was added to the dextran solution over a 5-15 minute period using vigorous overhead stirring in a five gallon cylindrical tank. After the periodate addition was completed, the reaction mixture was stirred at room temperature for about an additional four hours. About 5000-6000mL distilled water were further added to the reaction mixture over the four hour period to reduce the viscosity of the solution. After the four hours, the 12L reaction volume had an initial specific conductivity of $7.40 \text{ mmho-cm}^{-1}$ and an initial pH of 2.65. The reaction mixture was then desalted using a hollow fiber cartridge. Washing was done using about 100 liters of distilled water to obtain 6000 to 9000mL of washed, oxidized dextran solution having a specific

30

conductance of about 6-20 $\mu\text{mho}\cdot\text{cm}^{-1}$ and pH of 6.5-7.0. Since the dextran aldehyde solution is prone to gelation at ambient temperature, it was first made certain that the dextran aldehyde was completely dissolved before adding DAP. Then, the first portion of DAP, 70mL of pure liquid, was added over about 5 minutes to the desalted, oxidized dextran solution. The resulting solution immediately began to show formation of a gel, which persisted for another 5-10 minutes before redissolving as a yellow solution. The reaction mixture was then put on an ice bath to maintain a reaction temperature of 8-10°C and stirred vigorously before a second portion of 70mL DAP was added over a period of 5 minutes. After an additional 10 minutes of stirring, the third and final 70mL portion of DAP was added to the reaction mixture. The total DAP addition and reaction time was 45 minutes. Then, 70g, 5.00mol, of sodium borohydride in 700mL of 1mM aqueous potassium hydroxide solution were added to the reaction mixture at 8-10°C over about 10-15 minutes with overhead stirring. After the sodium borohydride addition was completed, the reaction mixture was stirred for an additional two hours until the yellow Schiffs' base color had disappeared. The reaction mixture was then desalted using the hollow fiber cartridge. In one run at a total volume of 7500mL, the initial specific conductance was 30.3 $\text{mmho}\cdot\text{cm}^{-1}$ and the initial pH was 11.79. About 80L of distilled water were used to produce about 1600mL of crosslinked 5X-aminodextran solution having a specific conductance of 10-20 $\mu\text{mho}\cdot\text{cm}^{-1}$ and pH of 7.0-8.0. The aminodextran solution was filtered through a 1.6 μm glass filter and lyophilized for a minimum of 72 hours to produce 75-90g (15-18% yield) of flaky, white to pale yellow crystals. Analyses for 5X-Amdex, lot 1-5, which gave a good yield of conjugates were C=41.38%, H=7.81%, N=4.15%, O=45.64%, I=97ppm, B=590ppm. The empirical formula was $\text{C}_{11.6}\text{H}_{26.1}\text{O}_{9.6}\text{N}$, which is similar to the formula $\text{C}_{11.2}\text{H}_{20.3}\text{O}_{7.3}\text{N} \cdot 2\text{H}_2\text{O}$ based on 4 units of glucose per one unit of 1.5 diaminopropane-substituted sugar ring. Thus, the degree of substitution of DAP in dextran was 1/5. Similar procedures were used in the preparation of 5X-Amdex, lot 2-2, except 1/3 x DAP was added in two portions to give a product which analyzed as C=40.44%, H=7.75%, N=3.48%, O=48.48% with a degree of substitution of DAP of 1/8.

High diamine concentrations caused depolymerization, and thus gave significantly lower molecular weight aminodextrans than the starting dextran. β -elimination and thereby depolymerization [Besemer, A.C., et al, in *Cellulose Derivatives: Modification, Characterization, and Nanostructures*, T.J. Heinze and W.G. Glasser, Eds. (ACS Symposium Series 688, American Chemical Society, Washington, DC, 1998), Chap.5, pp. 73-82.] has been previously noted in various oxidation reactions of glucans such as cellulose and starch.

The periodate oxidation of glucose units in dextran produced by Leuconostoc mesenteroides NRRL B-512 was shown [Jeanes, A. and Wilham, C.A., J. Amer. Chem. Soc. 72, 2655 (1950); Van Cleve, J.W., et al., J. Amer. Chem. Soc. 78, 4435 (1956)] to release one mole of formic acid per mole of reacted glucose unit by 95% of the anhydroglucose residues. Thus, the overall redox equation for a two-step periodate oxidation reaction is $2\text{IO}_4^- + \text{C}_6\text{H}_{10}\text{O}_5 \rightarrow 2\text{IO}_3^- + \text{C}_5\text{H}_6\text{O}_4 + \text{HCOOH} + \text{H}_2\text{O}$, requiring 2mol periodate per 1mol glucose unit or 2mol aldehyde for complete reaction. However, in 5X-Amdex preparations only 1mol periodate per 2.5mol glucose units or 2mol periodate per 5mol glucose units were used so that the theoretical degree of substitution is 1/5, i.e., 1 glucose unit out of 5 units in dextran is substituted with 2 aldehyde groups. Thus, the maximum degree of substitution of dextran with DAP is also 1/5, i.e., 1 in 5 glucose units in dextran is substituted with 2 DAP groups, assuming no crosslinking of aldehyde groups by DAP.

Some 5X-Amdex lots require further description. In particular, the reaction mixture of the 5X-Amdex, lot 11-6, after addition of DAP and sodium borohydride, was adjusted to pH 8.5 with aqueous hydrochloric acid. It was then desalted, concentrated, and freeze-dried in the previously described manner. Elemental analyses for 5X-Amdex, lot 11-6, were C=39.72%, H=7.77%, N=4.44%, Cl=2.81%, O (by difference)=45.26%. The empirical formula based on actual analyses was $\text{C}_{10.4}\text{H}_{24.3}\text{O}_{8.9}\text{NCl}_{0.25}$. The chloride analysis showed that 1 out of 4 total amine (primary and secondary) groups had a chloride counterion. Assuming only primary amine groups would be protonated near neutral pH to which the reaction mixture was desalted prior to lyophilization, this implies that 50% of the diaminopropane groups in aminodextran are bridging or crosslinking groups between dextran chains. These bridging DAP groups contain only two secondary amino groups. Thus, idealized repeating units for solely the substituted glucose residues of aminodextran would contain the following sequences: (a) 1 bridging DAP, 2 non-bridging DAP; 2 bridging DAP; 2 non-bridging DAP, 1 bridging DAP; (b) 2 bridging DAP; 2 bridging DAP; 4 non-bridging DAP; or some permutation of either of the (a) or (b) sequences. A portion of the lyophilized aminodextran hydrochloride was dissolved in distilled water and deionized in batchwise fashion with mixed bed (H^+ , OH^- form), Bio-Rad AG 501-X8 resin, until the specific conductivity of the supernatant was minimized. The resin was removed by filtration of the suspension through rayon cloth and the aminodextran (~50mg/mL) in the filtrate was fractionated by precipitation with acetone (0-43% cut). The solid precipitate was washed with acetone and dried in a vacuum dessicator under silica gel. Elemental analyses of this

deionized and fractionated material gave C=45.55%, H=7.03%, N=3.82%, Cl < 0.5%, O (by difference)=43.60%, showing that chloride ion had been removed.

Example 2 - Light scattering, viscosity, and refractive index data

- 5 90° light scattering was measured for dextran and aminodextrans at 10mg/mL in distilled water in a 1cm path cell with the COULTER® N4MD sub-micron particle analyzer. Values ranged from 7.4×10^4 to 1.1×10^5 counts/sec for dextran, T-2M; from $2.9\text{-}3.7 \times 10^4$ counts/sec for 1X-Amdex lots at 10mg/mL; from 2.5×10^4 to 1.2×10^5 counts/sec for 5X-Amdex lots at 10mg/mL versus distilled water at 4.5×10^3 counts/sec.
- 10 Molecular data for eleven samples, one dextran and ten aminodextrans, determined from duplicate batch analyses by the Viscotek (Houston, TX) triple detector system [Haney, M.A., Gillespie, D., and Yau, W.W., Today's Chemist at Work 3(11), 39 (1994)] are summarized in Table 1. The instrumental system consists of a model T-60 differential viscometer/light scattering dual detector and a model LR40 differential laser refractometer
- 15 with a 670.0nm diode laser source. The principles of the method and analyses have been described [Haney, cited above]. The samples were run at a concentration of 0.7 to 1.0 mg/mL in 0.2M aqueous sodium nitrate solution through a column consisting of a 50' coil of 0.01" i.d. stainless steel tubing without any column packing in batch mode. Two dissolution protocols were followed: 1. By minimum heating at ~70-80°C for 5-10min for samples 1, 3,
- 20 5, 6, and 8 ; 2. By first soaking at room temperature for 1-2 hours and then heating at ~70-80°C for 30min for samples 2, 4, 7, 9, 10, and 11. The responses of the three primary detectors are as follows: light scattering, $M \times (dn/dc)^2 \times c$; viscometer, $IV \times c$; refractometer, $dn/dc \times c$. Right angle light scattering gives the molecular weight when combined with viscometry detection. The 90° LS is corrected for angular dissymmetry using
- 25 the Debye equation, together with the molecular size information provided by the viscometer. Viscometry yields the molecular density, which is related to conformation and branching, and the refractometer measures concentration of sample, providing direct determination of the refractive index increment, dn/dc , of the polymer sample. The hydrodynamic volume of a polymer molecule in solution, related to the cube of its radius of gyration, R_g , is directly
- 30 proportional to the intrinsic viscosity (IV or η) and the weight average molecular weight (M_w), divided by Avogadro's number. The accuracy of R_g values determined by the triple detector system is claimed to be within 0.5nm.

Table 1. Triple Detector System Data for Dextran and Various Aminodextrans.

Sample	Conc., mg/mL	dn/dc, mL/g	M _w , kDa	IV, dL/g	R _g , nm	R, nm
1. 5X-Amdex, lot -11	0.860	0.155	414	0.262	15.6	38.2
2. 5X-Amdex, lot -11	1.940	0.132	25.6	0.0602	3.79	9.28
3. 1X-Amdex	0.940	0.155	1,044	0.442	25.2	61.7
4. 1X-Amdex	3.480	0.132	93.9	0.205	8.80	21.5
5. Dextran, T-2M	0.800	0.147	2,102	0.609	35.5	87.0
6. 5X-Amdex, lot 1-5	0.800	0.190	70.0	0.167	7.38	18.1
7. 5X-Amdex, lot 1-5	3.010	0.132	34.4	0.100	4.96	12.1
8. Amdex-3M	0.770	0.155	2,999	0.674	41.3	101.2
9. 5X-Amdex, lot -69	2.400	0.132	69.95	0.141	7.06	17.3
10. 5X-Amdex, lot 11-6	2.610	0.132	44.5	0.0999	5.40	13.2
11. 5X-Amdex, lot 2-2	2.390	0.132	168.4	0.186	10.35	25.3
Dextran *			54,600		70.0	
Dextran **			65			25.0
Dextran **			20			20.0
Dextran **			500			45.0

* Bovey, F.A., *J. Polym. Sci.* **35**, 167 (1959).

Titova, E.F., et al., *Farmatsiya* **23(5), 12 (1974).

5

Data for eleven samples were used to construct a Mark-Houwink plot of log(IV) versus log(M_w) as shown in Fig. 1. Linear regression analysis for all data gave a correlation coefficient of 0.976, a Y-intercept of -3.062, and a slope of 0.451. The slope corresponds to the exponent in the Mark-Houwink-Sakurada equation, $[\eta] = KM^a$, and in the above samples the value is very similar to the $a = 0.50$ one obtained for the linear fraction of dextran of 20,000 to 100,000 Da in water at 25°C as compiled [Kurata, M. and Tsunashima, Y., Polymer Handbook, J. Brandrup and E.H. Immergut, Eds. (Wiley-Interscience, New York, 1989) Chap. VII, pp. 1-55.]. This value of the exponent, $a = 0.50$, has been established for linear, flexible polymers under 'theta' temperature or solvent conditions, whereas the branched fraction of dextran of 800,000 Da in water at 25°C gave $a = 0.20$. It was therefore concluded that the aminodextrans behave as flexible, linear chains arranged in a compact,

15

globular structure in aqueous sodium nitrate solution and the positive charges of primary amino groups in 5X-Amdex are not sufficient to affect the compact dextran structure. The radius of gyration for a randomly coiled, linear, polymer molecule has been derived from random walk statistics as $R_g^2 = 1/6 nl^2$, where n is the number of statistical segments in the polymer chain and l is the length of each statistical segment. Also, the mean square end-to-end distance in a random coil is given by $R^2 = nl^2$ [Hiemenz, P.C., Principles of Colloid and Surface Chemistry (Marcel Dekker, New York, ed. 2, 1986) pp. 102-107]. Thus, it becomes possible to use the accurate R_g and mass average molecular weight values obtained from light scattering and viscosity, and elemental analyses (empirical formulae and degree of substitution) to calculate the root mean square end-to-end distance, R , the average molecular mass per segment, M_i , the number of statistical segments, and a statistical segment length in each polymer. These latter values can then be compared to the length of a single unit of 1,6-linked glucose reported [Bovey, F.A., J. Polym. Sci. 35, 167 (1959)] as about 8 Å long. Statistical segment lengths were 7.5 to 9.0 Å for the aminodextrans. Free rotation about the methylene group between residues of 1,6-glucosyl units in dextran appears to confer extra flexibility on the dextran chain in contrast to the rigidity of the chain of 1,4-glucosyl units in cellulose nitrate [Doty, P., et al., J. Amer. Chem. Soc. 75, 754 (1953)] in which glucose residues are joined only by an ether linkage. Previous studies of dextran of molecular weight greater than 2,000 Da have all indicated a globular structure [Bovey, cited above; Titova, cited above] in contrast to the open, extended structures of fiber and extracellular matrix polysaccharides such as cellulose and proteoglycans.

Example 3 - Gel Electrophoresis of Aminodextrans

Phosphate-buffered saline, 1xPBS, pH 7.1-7.3, and conductivity 13,500-15,500 $\mu\text{mho}\cdot\text{cm}^{-1}$, was prepared by dilution with distilled water from a 20xPBS stock solution, which contains 26.9 g dm^{-3} of K_2HPO_4 , 6.4 g dm^{-3} of KH_2PO_4 , and 170.0 g dm^{-3} of NaCl . Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of aminodextrans were run at 400V (65V-h) on the Pharmacia PHAST system, using a 4-15 gel gradient for the 30 to 300 kDa molecular weight range and SDS buffer strips. The use of this system for aminodextrans is made possible by the protonation and, thus, charging of primary amine groups at pH 8.0 of SDS buffer strips and the selective electrostatic interaction between negatively-charged sulfonate groups of the widely-used Coomassie blue stain (Pierce Catalog) and protonated amine groups. Since electrophoresis, applied to the study of synthetic polyelectrolytes, has been shown [Smisek, D.L. et al., Macromolecules 22, 2270

(1989)] to provide a more detailed molecular weight distribution than size exclusion chromatography, we had hoped to obtain an accurate measure of the size distribution in aminodextrans from the spread of bands in the electrophoretograms. Some lots of solid aminodextran resisted dissolution in aqueous media; thus, two protocols were needed to test samples for complete dissolution. In protocol 1, minimum heating of samples in distilled water at ~70-80°C was carried out for 5-10 min whereas, in protocol 2, the samples were similarly heated for 30 min. Both dissolution protocols were used to prepare 1 mg/mL Amdex solutions in 1xPBS buffer, each mixed 1:1 with SDS buffer, which were then run together with a high molecular weight (200, 116, 97, 66, and 45 kDa) standards sample. Gel electrophoresis bands stained with Coomassie blue for the two runs are shown in Fig. 2. Molecular weight ranges were estimated for the aminodextrans from the range of the heaviest blue stain in each lane of the gel, referenced to the relatively narrow band positions of five standards in the same gel. 5X-Amdex lots 1-5, 2-2, -11 and 11-6, and 1X-Amdex lot -75 gave molecular weight ranges of about 30-75, 60-190, 50-150, 35-250, and 150-250 kDa, respectively, for protocol 1 dissolution and about 30-75, 55-175, 40-90, 30-110, and 150-250 kDa, respectively, for protocol 2 dissolution. The 5X-Amdex lots showed the largest change to lower molecular weight fragments with the more extensive protocol 2 dissolution procedure. In most cases, the average molecular weight determined from the Viscotek triple detector (light scatter, viscosity, refractive index) system measurements fell in the middle of the range shown by SDS-PAGE results, even though the position of species in electrophoretograms depends strictly on their charge-to-size ratio.

Example 4 - Preparation of CdS Nanoparticles of the Invention

All solutions related to the preparation of CdS nanoparticles were freshly prepared and were filtered through 0.22 µm pore size membranes before each experiment. The UV-visible spectra of CdS dispersions were recorded with a Perkin Elmer Lambda 6 UV/vis or Beckman DU640 spectrophotometer. The size of CdS nanoparticles was determined from the onset of light absorption based on the previously published calibration curve [Weller, H., et al., Chem. Phys. Lett. 124, 557 (1986)]. The luminescence emission spectra of Amdex-CdS dispersions were recorded with the Spex Fluorolog instrument equipped with a Tracor Northern TN 6500 rapid scan spectrometer detection system, using 380 nm excitation.

A. Controlled double-jet precipitation process

The equipment for the controlled double-jet precipitation (CDJP) was described in detail previously [Wang, L., et al., Colloid Polym. Sci. 275, 593 (1997); Schultz, M., and

Matijevic, E., Colloids Surf. 131, 173 (1998); Lee, S.-H. et al., J. Colloid Interface Sci. 186, 193 (1997)]. In a typical run, equal volumes (50 cm^3) of solutions containing the Cd(II) salt and Na_2S , respectively, were simultaneously introduced by peristaltic pumps into the jacketed reactor at a constant flow rate of $10\text{ cm}^3\text{ min}^{-1}$. The reactor contained 100 cm^3 of an aqueous 5x-aminodextran solution, stirred at 700 rpm. The reactor outer jacket was connected to a thermostated circulating water bath kept at $25.0 \pm 0.1^\circ\text{C}$. The mixing of the solutions immediately yielded CdS sols, which were further stirred for 15 min. The summary of experimental conditions used in these experiments is given in Table 2, below.

To establish the dependence of the particle size and of the optical properties of the resulting CdS dispersions on the type of the anion present in Cd(II) salts, equal volumes of $1 \times 10^{-3}\text{ M}$ solutions of CdCl_2 , $\text{Cd}(\text{NO}_3)_2$, CdSO_4 , and $\text{Cd}(\text{ClO}_4)_2$, respectively, were reacted with a $1 \times 10^{-3}\text{ M}$ Na_2S solution. The final concentration of CdS and of 5x-aminodextran was $2.5 \times 10^{-4}\text{ M}$ and 2.5 g dm^{-3} respectively. To establish the effect of the reactant concentrations, the experiments were also carried out using higher (up to $1 \times 10^{-1}\text{ M}$) concentrations of CdSO_4 and Na_2S .

To enhance the luminescence intensity of the synthesized CdS dispersions, in some experiments a higher concentration of Cd(II) salts ($1.3 \times 10^{-3}\text{ M}$) was used, while the concentration of Na_2S was kept the same, still maintaining the same volumes of the reactant solutions. For this reason, a few drops of 0.1 M NaOH solution were also added to the prepared CdS dispersions to reach $\text{pH} \sim 11$.

B. Rapid mixing of reactant solutions

This procedure consisted of rapidly adding 100 cm^3 of a CdSO_4 solution into 100 cm^3 of a stirred Na_2S solution containing 5 g dm^{-3} of 5x-aminodextran, keeping $[\text{Cd}^{2+}]/[\text{S}^{2-}] = 1$. The concentrations of the CdSO_4 and Na_2S solutions used in these experiments are given in Table 2.

Table 2. Conditions for the preparation of nanosized CdS particles by the CDPJ and rapid mixing processes. The final concentration of 5x-aminodextran, lot 11-6 is 2.5 g dm^{-3} .

5	Initial concentrations of CdSO ₄ + Na ₂ S solns			Final CdS concentration	Estimated Particle Size	Suspension
	<u>Sample (M)</u>	<u>pH</u>	<u>(M)</u>	<u>(nm)</u>	<u>Stability</u>	
	CDJP process					
	a	0.001	9.1	0.00025	2.7	stable
	b	0.01	9.0	0.0025	4.0	stable
	c	0.1	8.8	0.025	~8.0	stable
	Rapid mixing process					
	a 1	0.0005	9.1	0.00025	2.2	stable
	b 1	0.005	9.0	0.0025	3.1	stable
	c 1	0.05	8.8	0.025	-	unstable

10

In order to evaluate the effects of different aminodextrans (5x-aminodextran, lots 11-6, 1-5, and 2-2, 1x-aminodextran, Amdex-3M, and Amdex-3000) on the size, stability, and fluorescence, CdS nanoparticles were prepared by the rapid mixing 50 cm^3 of a $1.5 \times 10^{-3} \text{ M}$ Cd(ClO₄)₂ solution with 50 cm^3 of a solution containing $1 \times 10^{-3} \text{ M}$ Na₂S and varying concentrations of aminodextrans between 0.05 and 16 g dm^{-3} . The same experiments were carried out with dextran 500,000, in concentrations of 2, 5, and 20 g dm^{-3} , and with 5 g dm^{-3} of dextran 20,000. The mixing of the solutions immediately yielded CdS sols, which were further stirred for 15 minutes. In all samples the pH was raised with NaOH to ~ 10.5 .

15

C. Size of Nanoparticles Prepared by (A) CDPJ and (B) Rapid Mixing

20

The absorption spectra of CdS dispersions prepared with different Cd(II) salts and 5x-aminodextran, lot 11-6 as stabilizer (Fig. 3) and diluted to $[\text{CdS}] = 2.5 \times 10^{-4} \text{ M}$ were used to evaluate the size of the resulting nanoparticles. Thus, the sols obtained with the CdCl₂ solution show the absorption onset of $\lambda_0 \sim 425 \text{ nm}$ (spectrum a), corresponding to the average particle size of 2.3 nm, while those precipitated with Cd(NO₃)₂, CdSO₄, and Cd(ClO₄)₂ solutions had a diameter of 2.7 nm ($\lambda_0 \sim 455 \text{ nm}$, spectra b, c, and d).

25

Fig. 4 displays the change in the absorption spectrum of the CdS dispersion with time during the CDPJ process, after dilution to $[\text{CdS}] = 5 \times 10^{-4} \text{ M}$. The shift in the absorption onset towards higher wavelengths indicates an increase of the particle size from 2.3 nm after 6 seconds to approximately 8 nm after 5 min.

30

The effect of different concentrations of CdSO₄ and Na₂S solutions on the particle size of the resulting CdS dispersions containing 5x-aminodextran, lot 11-6 is shown in Fig. 5. For comparison purposes all dispersions were diluted to the same concentration of $[\text{CdS}] = 2.5 \times 10^{-4} \text{ M}$. The onset of absorption rose from 460 nm to 540 nm, as the reactant

concentrations were increased from 1×10^{-3} to 1×10^{-1} M. The former onset value corresponds to particles of 2.7 nm, while the latter is indicative of the formation of larger particles, whose size can not be established from the calibration curve given in Weller, H., et al., Chem. Phys. Lett. 124, 557 (1986). It may, however, be estimated from the results reported in Weller, H., Angew. Chem. Int. Ed. Engl. 32, 41 (1993), that the size of these particles is approximately 8 nm. Analogous trend was observed with CdS nanoparticles prepared by the rapid mixing process (Fig. 6), i.e., the particle size shifted from 2.2 to 3.1 nm when the molar concentrations of CdSO₄ and Na₂S were changed from 5×10^{-4} to 5×10^{-3} M.

The results obtained with the two procedures suggest that, under the same conditions, the CDJP and rapid mixing techniques yielded dispersions containing CdS nanoparticle. However, the rapid mixing yielded consistently smaller CdS particles than the CDJP (Table 2). Furthermore, dispersions obtained at higher reactant concentrations were more stable when the CDJP process was employed.

These differences in suspension stability and particle size at otherwise identical final concentrations of CdS suggest, that the mechanism of particle formation by the two processes differs. During the CDJP the reactants are simultaneously fed into the reactor, allowing for a continuous formation of nuclei, which then may aggregate into larger clusters. The particle growth is confirmed by the gradual increase in the absorption onset values during the precipitation process (Fig. 4). These results agree with the observed changes in the suspension color: from pale yellow at the beginning of the precipitation process, to light orange at the end of it. The rapid mixing process results in an instantaneous larger nuclei concentration because of the higher supersaturation. These nuclei then grow to smaller particles (Table 2), probably by the diffusion mechanism. The lower stability of these dispersions is probably due to the larger specific surface area of smaller particles, which means that larger amounts of the polymer are required to stabilize the system.

The luminescence spectra of CdS suspensions, prepared by the CDJP process, show that at equal final concentrations of CdS at pH approximately 9 the emission intensity of particles obtained with CdSO₄ is much lower than that of systems made with other Cd(II) salts (Fig. 7). In all cases the luminescence intensity maximum is at ~540 nm with the band gap edge at 500 nm and the trap luminescence at longer wavelengths. Thus, the type of anions supplied with cadmium salts has a strong effect on both the size and the emission intensity of CdS nanoparticles, as demonstrated in Figs. 3 and 7. The effects of anions on the luminescence quenching has been described previously [Henglein, A., Ber. Bunsenges. Phys. Chem. 86, 301 (1982)], who assumed that the positive holes on the semiconductor surface,

prior to their recombination with electrons, form ion-pair-type surface complexes with the anions, which quench the luminescence. Among the anions tested, the SO_4^{2-} ions probably have the strongest affinity towards the CdS surface, thus making the emission least intense.

The activation of luminescence by increasing the system pH in the 30% molar excess of Cd^{2+} is clearly demonstrated in Fig. 8. The emission intensity of the same CdS suspension is significantly higher at pH 11 than at pH 9. This significant increase in the emission intensity of CdS dispersions at higher pH values (Fig. 8) may be caused by the formation of a $\text{Cd}(\text{OH})_2$ layer on the CdS surface, which blocks surface imperfections responsible for the trapping of charge carriers. The $\text{Cd}(\text{OH})_2$ layer also increases the rate of radiative recombination at the expense of the non-radiative one [Weller, H., Angew. Chem. Int. Ed. Eng. 32, 41 (1993); Spanhel, L., J. Am. Chem. Soc., 109, 5649 (1987)].

D. The effect of different dextrans and aminodextrans on the size, stability, and luminescence of CdS nanoparticles

The absorption spectra (Fig. 9) of CdS nanoparticles show the absorption onset of 515 nm for all concentrations of dextran 500,000 used in the preparation. The same absorption onset was also obtained with a CdS dispersion containing 5 g dm^{-3} of dextran 20,000. The particle diameter is estimated to be $> 5 \text{ nm}$ [Henglein, A. Chem Rev. 89, 1861 (1989); Fojtik, A., et al, Ber. Bunsenges. Phys. Chem., 88, 969 (1984)]. None of these suspensions were luminescent.

The use of amine-derivatized polysaccharides, aminodextrans, has a significant effect on the size and absorption properties of CdS nanoparticles; i.e., in the presence of high polymer concentrations, the absorption spectra are well structured and steep absorption onsets are in the blue wavelength range (Fig. 10) indicating a narrow size distribution of the dispersions. Specifically, increasing the concentrations of 1x-aminodextran from 0.05 to 16 g dm^{-3} , while keeping the same concentrations of other reactants, resulted in shift of the onset of the absorption from 520 nm (spectrum h, particle size $> 5 \text{ nm}$) to 420 nm (spectrum a, particle size = 2.3 nm) (Fig. 10). The CdS dispersions prepared with this polymer in concentrations $> 1 \text{ g dm}^{-3}$ remained stable for about one month, while those with smaller amounts were stable only for a few days.

Fig. 11 shows that the relative luminescence intensity is higher with increasing concentration of 1x-aminodextran, with a maximum at 490 nm, shifting to 500nm at the largest Amdex concentration, and a bandwidth of about 150nm.

The behavior of the 5x-aminodextran, lot 2-2 –CdS dispersions is rather similar to that of 1x-aminodextran-CdS dispersions. Fig. 12 compares the mean diameters of CdS

particles as a function of the concentration of 5x-aminodextran, lot 2-2 and 1x-aminodextran. Specifically, Fig. 12 shows that the mean diameter of CdS nanoparticles decreases as the concentrations of aminodextrans become higher.

The luminescence spectra of 5x-aminodextran, lot 2-2-CdS dispersions show a
5 maximum at 490 nm for low Amdex concentrations, shifting to about 500nm at the highest concentration, and maintaining a bandwidth of about 150nm (Fig. 13).

Spectral features of all Amdex-CdS dispersions were placed on a relative basis by using the identical instrument settings (5 and 2.5nm slits), excitation source, and fluorescence cell for all measurements. Amdex concentrations were 2.5, 5.0, 10, and 20 g dm⁻³ while CdS
10 concentrations were 5x10⁻⁴, 1x10⁻³, 5x10⁻³, and 1x10⁻² M for most runs. 1x-aminodextran-CdS dispersions showed luminescence intensities increasing from about 40 to 90 in arbitrary units for the two lowest CdS concentrations. Little or no luminescence intensity was detected at CdS concentrations greater than 1x10⁻³ M. 5x-aminodextran, lot 2-2
-CdS dispersions had intensities ranging from 70 to 50 a.u. for the two lowest CdS
15 concentrations, and <5 a.u. for concentrations greater than 1x10⁻³ M. Luminescence bandwidths were narrower, about 100nm, at lower Amdex concentrations. 5x-aminodextran, lot 11-6 -CdS sols showed luminescence intensities at about 490nm ranging from 100 to 75 a.u. for the lowest CdS concentration, and narrower luminescence bandwidths of 100nm at all Amdex concentrations. Again, the highest two CdS concentrations gave luminescence
20 intensities <5 a.u. at the maximum. 5x-aminodextran, lot 1-5 -CdS sols showed luminescence intensities at 490nm of about 80 to 130 a.u. for the lowest two CdS concentrations with narrower bandwidths of about 100nm. Hydrosols at the higher two CdS concentrations all had maximum luminescence intensities below 15 a.u. Amdex-3M-CdS suspensions at the lowest CdS concentration showed luminescence intensities at maxima between 530 and
25 540nm of 2 to 5 a.u., and bandwidths of about 100nm. The sols prepared at higher CdS concentrations were mostly unstable, showing formation of a white precipitate which settled out within several hours. The average CdS particle size from the absorption onsets ranged from 3.2 to 4.1 nm. Amdex-3000-CdS dispersions gave luminescence intensities at band maxima between 450 and 510nm of 20 to 190 a.u. , and the narrowest bandwidths of 75 to
30 100nm, for the two lowest CdS concentrations. Sols prepared at the two highest CdS concentrations were unstable or gave intensities < 5 a.u. CdS nanoparticle diameters obtained from absorption onsets were very low, ranging from 2.4 to 1.9 nm for the lowest CdS concentration.

It is also instructive to use the above concentrations of aminodextran and cadmium sulfide particles to compare the numbers of CdS nanoparticles of 2.8 nm diameter per mL that would be formed in 200 mL of 1×10^{-3} M CdS against the number of 5x-Amdex, lot 1-5 molecules at 20 g dm^{-3} in the same volume. For 2×10^{-4} mol CdS ($144.47 \text{ g mol}^{-1}$) with a bulk density of 4.50 g cm^{-3} and volume of 11.49 nm^3 per nanoparticle, we obtain 2.8×10^{15} particles/mL. 5x-Amdex at 20 g dm^{-3} and average MW of 34.4 kDa gives 3.5×10^{17} molecules/mL. Thus, the ratio of nanoparticles-to-molecules of 5x-Amdex is about 1:100 at 20 g dm^{-3} ; however, at 0.2 g dm^{-3} of 5x-Amdex the ratio is about 1:1. Stabilities and luminescence intensities of aminodextran-CdS dispersions are much greater when they are prepared with excess polymer concentrations in the range, 1-20 g dm^{-3} .

The range of polymeric carrier, aminodextran, characteristics has been expanded to include a wide variety of aminodextrans. Of the aminodextrans used in CdS nanoparticle preparations at 20 g dm^{-3} , the order of increasing total amine concentration was: Amdex-3M [$8.7 \times 10^{-4} \text{ M}$] < Amdex-3000 [$1.1 \times 10^{-2} \text{ M}$] < 1X-Amdex [$1.2 \times 10^{-2} \text{ M}$] < 5X-Amdex, lot 2-2 [$8.2 \times 10^{-2} \text{ M}$] ~ 5X-Amdex, lot 11-6 [$8.2 \times 10^{-2} \text{ M}$] < 5X-Amdex, lot 1-5 [$9.8 \times 10^{-2} \text{ M}$]. The concentrations of total amine (primary and secondary) in each 20 g dm^{-3} aminodextran solution were calculated from data shown in Table 3.

Table 3. Amine substitution data for aminodextrans.

	MW, Kda	Glucose units per molecule	Degree of subst	Mol diamino- propane per mol Amdex	Mol amine per mol Amdex
5X- Amdex, lot 1-5	34	209.7	2/5	83.9	167.8
5X- Amdex, lot 11-6	44.5	274.5	1/3	91.4	182.8
5X- Amdex, lot 2-2	168.4	1038.9	1/3	345.9	691.8
1X-Amdex	93	573.7	1/20	28.7	57.4
Amdex- 3M	3,000	18,507	1/142		130
Amdex- 3000	3	18.5	1/11		1.7

- 5 The order of increasing luminescence emission intensity was: Amdex-3M [about 3-4] < 5X-Amdex, lot 2-2 [50] < 5X-Amdex, lot 11-6 [about 60-80] < 1X-Amdex, [about 90] < 5X-Amdex, lot 1-5 [about 90-120] < Amdex-3000 [about 180-190]. Note that the 5X-Amdex lots are not aligned with the general trend of increasing luminescence emission with increasing total amine concentration; however, among lots of 5X-Amdex, the trend is maintained. The
- 10 order by increasing size of Amdex in aqueous solution is: Amdex-3M [R = 101.2nm diameter] > 5X-Amdex, lot 2-2 [25.3nm] > 1X-Amdex [21.5nm] > 5X-Amdex, lot 11-6 [13.2nm] > 5X-Amdex, lot 1-5 [12.1nm] > Amdex-3000. Note that the smallest aminodextrans by size have yielded CdS-aminodextran conjugates with the most intense luminescence emission. Also, the largest CdS-Amdex nanoparticles showed the least
- 15 luminescence intensity since the largest Amdex (3M Da) had the fewest amino groups (1/142 degree of substitution) and the lowest amine concentration.

It should be noted, that it was not possible to prepare luminescent CdS nanoparticles using dextrans, but strong luminescence could be achieved with aminodextrans, depending on their concentration in the reaction mixture. This finding suggests that the presence of amino

20 groups in the dextran molecules and a high pH medium are essential for the activation of

CdS nanoparticle luminescence. The higher luminescence intensity of particles prepared with 5x-aminodextran, lot 2-2 than of those obtained with 1x-aminodextran, is most likely caused by the difference in the degree of substitution of these two polymers. The obvious question is how amino-groups enhance the luminescence intensity. Previous studies have reported strong sensitivity of the luminescence quantum yield to chemical modification of the cluster surface [Fojtik, A., Weller, H., Koch, U., and Henglein, A., Ber. Bunsenges. Phys. Chem. 88, 969 (1984); Rossetti, R., et al., J. Chem. Phys. 80, 4464 (1984)]. The wurtzite or zinc blende crystalline structures of CdS nanocrystals leave surface cadmium atoms with fewer bonds to nearest neighbors of sulfur atoms, three instead of the usual four in the interior of the nanocrystal. It is known that the semiconductor nanoparticles have a high density of surface defect sites, which cover a broad range of energies [Fojtik, A., cited above; Henglein, cited above; Nozik, A., J. Phys. Chem. 90, 12 (1986)]. Most of such sites exist in the midband gap energies and are involved in trapping initially produced electron-hole pairs.

The investigation of Dannhauser and co-workers has shown that several tertiary amines significantly enhance luminescence intensity, when added to a suspension of CdS nanoparticles [Dannhauser, T. et al., J. Phys. Chem., 90, 6074 (1986)]. This effect was interpreted as due to the modification of midband gap states, probably associated with Cd^{2+} binding to amines. The latter raises the site energy, effectively removing these sites as efficient traps, thus increasing luminescence intensity.

Enhanced luminescence emission intensity from CdS nanoparticles was achieved by forming multiple nanoparticles in the domain of single polymer molecules of aminodextran. The nanoparticles of diameter 2-3nm are substantially smaller than the 5x-aminodextran, $R = 9.28$ to 25.3nm and $\text{MW} = 25.6$ to 168.4 Da, that was used subsequently in conjugations of monoclonal antibody. Thus, it is possible for more than one nanoparticle to be attached to a single molecule of 5x-aminodextran. This is similar to the conjugation of multiple numbers of phycoerythrin(PE) molecules together with monoclonal antibody to aminodextran, as described previously. PE is monodisperse with a molecular weight of $270,000$ Da and a diameter of 27.7nm . CdS nanoparticles can be similarly characterized. The number of atoms per particle of CdS is estimated from the volume per spherical particle of 2.8nm diameter as 11.49 nm^3 divided by the volume of a unit cell (0.5975nm edge for cubic cell) occupied by four CdS units or 8 atoms as 0.2133 nm^3 . The quotient ($11.49\text{ nm}^3 // 0.2133\text{ nm}^3 / 8$ atoms) yields 431 atoms. Since one-half of the atoms are cadmium and one-half, are sulfur, the molecular weight of a 2.8nm diameter CdS particle is estimated as $(215 \times 112.41 + 215 \times 32.06) = 31,000$ Da. The density of bulk CdS in the zinc blende structure is 4.50 g/cc , at least

4-fold larger than the density of a typical organic polymer; thus, the size of CdS particles is proportionally smaller than typical 5x-aminodextrans.

The main criteria for success in obtaining optimal yields of CdS nanoparticles with aminodextran, that produce large luminescence intensities and have reasonable stability to activating reagents appear to be the following: 1. high aminodextran concentration; 2. high concentration of amine (primary and secondary) groups in aminodextran; 3. high molecular weight of aminodextran; 4. excess Cd(II) ion concentration; 5. high pH.

The present experiments have demonstrated that the interaction between nanocrystal surfaces and the aminodextran can be controlled through changing the degree of substitution of amine groups in the aminodextran molecule, which makes it possible to tailor the size, stability, and optical properties of CdS dispersions by the choice of the composition and the concentrations of these polymers.

Example 5 - Preparation of ZnS Nanoparticles by the CDJP Process

In a CDJP process, 50 cm³ of zinc sulfate (ZnSO₄) and sodium sulfide (Na₂S) solutions were separately and simultaneously introduced at the constant flow rate of 10 cm³ min⁻¹ into 100 cm³ of an aqueous solution, containing 5x-aminodextran as the stabilizing agent. The dispersion was agitated with a stirrer at 700 rpm. All experiments were carried out at the constant temperature of 25°C.

The concentration of the reactants, i.e., zinc salt and sodium sulfide, was varied from 1x10⁻³ M to 1x10⁻² M, while the molar ratio was kept constant at [Zn²⁺]/[S²⁻] = 1. The concentration of 5x-aminodextran in the system was constant at 5 g dm⁻³. In changing the concentration of these solutions the ionic strength was varied, which may have affected the particle size. A summary of the precipitation conditions that were used in the formation of ZnS dispersions is given in Table 4.

Table 4. Conditions for the preparation of nanosized ZnS particles by the CDJP process in the presence of 5 g dm⁻³ 5x-aminodextran.

sample	[Zn ²⁺] & [S ²⁻] M	pH	color	absorption onset nm	bandgap eV
a	0.001	9.2	colorless	290	4.28
b	0.005	8.6	colorless	299	4.15
c	0.01	8.3	colorless	306	4.05

The precipitation of zinc sulfide by the CDJP process in the presence of 5x-aminodextran resulted in stable dispersions of nanosized particles. The difference in the

particle size can be recognized from the onset of the absorption, which shows the dependence of the particle size on the concentration of the reactants. The onset of the absorption determined from 5×10^{-4} M ZnS dispersions shifted from 290 nm (sample a) to 306 nm (sample c). These results correspond to quantum energies larger than that of ZnS as macroscopic solid (3.67 eV), indicating the formation of quantized ZnS nanoparticles. The bandgaps are somewhat larger in energy than those reported in the literature [Henglein, A. et al., Ber. Bunsenges. Phys. Chem. 87, 852-858 (1983); Weller, H. et al., Ber. Bunsenges. Phys. Chem. 88, 649-656 (1984); Dunstan, D.E. et al., J. Phys. Chem. 94, 6797-6804 (1990); Qi, L. et al., Colloids Surfaces 111, 195-202 (1996)], indicating the formation of extremely small quantized ZnS nanoparticles. Thus, 5x-aminodextran provides a good medium for preparation of nanosized ZnS particles by the CDJP process.

Example 6 - Preparation of Mixed CdS-ZnS Nanoparticles

Single CdS or ZnS nanoparticles were also prepared by rapid mixing of 50 cm³ of 2×10^{-3} M CdSO₄ or ZnSO₄ solutions with 50 cm³ of 2×10^{-3} M Na₂S solution containing 5 g dm⁻³ 5x-aminodextran. The final CdS or ZnS concentration was 1×10^{-3} M.

The rapid mixing of 50 cm³ of solution containing CdSO₄ and ZnSO₄ in a total concentration of 2×10^{-3} M (but in different ratios) with 50 cm³ of 2×10^{-3} M Na₂S solution led to the formation of mixed Zn_xCd_{1-x}S nanoparticles. The final Zn_xCd_{1-x}S concentration was 1×10^{-3} M while x value was varied as determined by the molar ratio of Cd²⁺ and Zn²⁺ contained in the solution.

The chemical composition and some properties of these nanoparticles are given in Table 5.

Table 5. Characterization of mixed CdS-ZnS nanoparticles.

sample	composition	pH	color	absorption onset nm	bandgap eV
a	ZnS	9.0	colorless	294	4.22
b	Zn _{0.7} Cd _{0.3} S	9.1	colorless	344	3.60
c	Zn _{0.5} Cd _{0.5} S	9.3	colorless	375	3.31
d	Zn _{0.3} Cd _{0.7} S	9.4	pale yellow	406	3.05
e	CdS	9.5	yellow	431	2.88

5 Single ZnS nanoparticles have an absorption onset at 294 nm, which corresponds to a bandgap of 4.22 eV, indicating the formation of extremely small quantized ZnS nanoparticles. Single CdS particles show an absorption onset at 431 nm, corresponding to an average particle size of < 2.5 nm. Absorption spectra of $Zn_xCd_{1-x}S$ nanoparticles were found to lie between those of CdS and ZnS nanoparticles. Absorption onsets systematically
 10 shifted towards shorter wavelengths, from 431 nm to 294 nm, on increasing the amount of zinc in $Zn_xCd_{1-x}S$. Mixed nanoparticles show a continuously tunable energy gap from single CdS nanoparticles to single ZnS nanoparticles.

 The absorption spectrum for the mixture of single CdS nanoparticles and single ZnS nanoparticles prepared separately with a Zn/Cd molar ratio of 1:1 shows two separate
 15 absorption edges, corresponding to those of single CdS and ZnS, which approximately reflects a superposition of CdS and ZnS spectra, unlike that of coprecipitated nanoparticles.

Example 7 - Metal Ion Coordination to Aminodextrans

 Crucial to the formulation of any coherent picture of the mechanism of formation of
 20 CdS nanoparticles in the presence of aminodextran in an aqueous medium is the initial possibility of metal ion binding to sites on the aminodextran polymer. Towards this goal experiments were conducted to react chromophoric, aqueous copper(II) ions with aminodextran, using dextran as a control. Lot -26 1X-Amdex, which was analyzed as $C_{49}H_{84}O_{40}N \cdot 3H_2O$ with an empirical weight of 1,381.2 Da, was used. Thus, the
 25 molecular weight of the smallest repeating unit with two diaminopropane units substituted in

one sugar ring is 5,525 Da. In one run, 2.000×10^{-4} mol or 1.105g of 1X-Amdex, lot -26 and the same amount of control, 1.105g of dextran, T-2M, were separately dissolved in 50 mL of distilled water. To each sample were then added, stepwise, 2.00×10^{-3} mol or 0.328g of sodium acetate dissolved in 10 mL of distilled water, followed by 2.00×10^{-3} mol or 0.465g of $\text{Cu}(\text{NO}_3)_2 \cdot 5/2 \text{H}_2\text{O}$ dissolved in 25 mL of distilled water. The total volume of each sample was adjusted to 100 mL with distilled water, and the mixtures were stirred magnetically for 3 days. The mixture of Cu(II)-dextran became cloudy and was filtered through an 0.45 micron filter before measuring its electronic absorption spectrum in the visible-to-near-UV region. After the mixing period, the Cu(II)-dextran sample gave pH = 5.31, conductivity = 6.05 mmho-cm⁻¹, $\lambda_{\text{max}} = 771\text{nm}$, and $A_{771} = 0.453$, while the Cu(II)-1X-Amdex sample gave pH = 5.79, conductivity = 5.68 mmho-cm⁻¹, $\lambda_{\text{max}} = 747\text{nm}$, and $A_{747} = 0.534$. Both samples were then separately washed with distilled water by membrane filtration (A/G Technology Corp. Model UFP-30-E-4 hollow fiber cartridge, 30,000 Da MW cut-off) to remove excess salts. After washing, the colorless Cu(II)-dextran sample gave pH = 6.53, conductivity = 4.25 $\mu\text{mho-cm}^{-1}$, and no detectable absorbance greater than 0.007 units between 400 and 900nm; whereas, the distinctly blue Cu(II)-1X-Amdex sample gave pH = 6.32, conductivity = 4.05 $\mu\text{mho-cm}^{-1}$, $\lambda_{\text{max}} = 630\text{nm}$, and $A_{630} = 0.050$. Assuming that the weak absorption bands originating from d-d transitions of the Cu(II) species before and after washing have not changed much in their molar extinction coefficients, then the approximately 10% remaining absorbance matches the amount of Cu(II) needed to exactly occupy all the doubly diaminopropane-substituted sugar sites of 1X-Amdex. All of the Cu(II)-1X-Amdex sample was freeze-dried to provide 0.765g of dried solid, so that the molar extinction coefficient of the 630nm absorption band was calculated to be about 35 dm³-cm/mol. Elemental analyses of the solid, 0.56% N and 0.54% Cu, showed that 85% of the 4N sites of doubly diaminopropane-substituted glucose residues were occupied by Cu(II). Molecular models of these DAP-substituted residues have shown that four-coordination of Cu(II) to the four nitrogen electron-pair-donor atoms of two diaminopropane units substituted on the same glucose residue of dextran is sterically feasible. The two six-membered chelate rings comprising of $\text{Cu}(\text{NH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N})_2$ - are consistent with known coordination chemistry of stable transition metal chelates. Intramolecular or intermolecular Cu(II) crosslinks between two diaminopropane units on different glucose residues are less favorable sterically. Similar binding of other divalent transition metal ions such as Zn(II) and Cd(II) is expected. The selectivity of 1X-Amdex for Cu(II) ions was shown with the same amounts of 1X-Amdex and Cu(II) as above, but in the presence of a 50-fold excess of Zn(II) ions from

Zn(NO₃)₂ • 6H₂O. The mixture was stirred overnight and then washed by membrane filtration to give a faint blue solution, pH = 6.75, conductivity = 4.15 μmho-cm⁻¹, λ_{max} = 618nm, and A₆₁₈ = 0.038. Comparison against absorbance when only Cu(II) was present gave 79% Cu(II) incorporation in the presence of excess Zn(II). Being in the same group IIB in the periodic table, cadmium(II) is expected to bind to aminodextrans in a similar way to Zn(II).

Example 8 - Preparation of T4 antibody-5X-Amdex-CdS conjugate

Coulter T4 monoclonal antibody, CD4 clone SFC112T4D11 (IgG1), was derived from hybridization of mouse NS/1-AG4 cells with spleen cells of BALB/cJ mice immunized with peripheral human T lymphocytes (T4 antibody from Beckman Coulter, Inc., Miami, Florida).

Emission and excitation spectra of T4-5X-Amdex-CdS conjugates were measured with a Shimadzu Model RF5000U spectrofluorimeter using a xenon lamp for excitation. Quasi-elastic light scattering, QELS (or photon correlation spectroscopy, PCS) and its analysis were obtained with a COULTER Model N4MD sub-micron particle analyzer with size distribution processor (SDP) analysis and multiple scattering angle detection with 632.8nm He/Ne laser excitation.

Standard primary amino functional group activation and conjugation procedures that are described in detail in the Pierce catalog [Pierce Catalog and Handbook, Life Science & Analytical Research Products, 1994/95, Pierce Chemical Company, Rockford, IL.] and other monologs [Wong, S. S., Chemistry of Protein Conjugation and Cross-Linking (CRC Press, Inc., Boca Raton, FL, 1991); Hermanson, G. T., Bioconjugate Techniques (Academic Press, San Diego, CA, 1996); Aslam, M. and Dent, A., Bioconjugation-Protein Coupling Techniques for the Biomedical Sciences (Grove's Dictionaries Inc., New York, NY, 1998)] were followed. Sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) was a Pierce product while 2-iminothiolane, L-cysteine free base, and iodoacetamide were Sigma grade.

In Run 7, ten milliliters of raw 5X-Amdex-CdS dispersion, prepared at a 20 g dm⁻³ 5X-Amdex, lot 1-5 concentration, were purified and buffer exchanged on a 2.5cm x 48cm G-25 Sephadex column equilibrated and eluted with 1xPBS, and collected in 120 drop (~3.6mL) fractions. Two luminescent bands were observed with a 366nm UV lamp, a narrow first band and a broader and brighter second band. Three of the brightest fractions(24-26) of the second band were combined into a 10.8mL volume. 0.200mL of sulfo-SMCC solution, 10mg/mL in

1xPBS, were used for activation. The mixture was roller mixed for one hour, and then separated on a G-25 Sephadex column [Pharmacia Biotech], retaining the two brightest fractions (23 and 24) of 7.2mL total volume. 25mg of 47.16mg/mL T4 antibody concentrate was activated with 0.161mL of 2.0mg/mL 2-iminothiolane solution in 1xPBS. 0.976mL of 1xPBS buffer solution was added to the mixture, which was then roller mixed for one hour. The mixture was purified on G-50 Sephadex [Pharmacia Biotech], retaining the middle fraction of the first band, containing 4.5mL of 3.831mg/mL or 17.240mg IT-T4. Conjugation of 7.2mL of sulfo-SMCC-5X-Amdex-CdS suspension with 4.5mL of IT-T4 solution was accomplished by roller mixing for two hours. The conjugation mixture was separated on a Bio-Gel A-5m column [Bio-Rad Laboratories], 2.5cm x 48cm, equilibrated with 1xPBS. Two initial broad, poorly separated, bands (fractions 22-30, 32.4mL and 31-40, 36.0mL) were retained, and each pooled and concentrated in Amicon Centri-Prep 30 tubes by centrifugation for 20min at 2000rpm in an IEC Centra-8 centrifuge to 3.7 and 2.8mL, respectively. Runs 9 and 10 were carried out in a similar way except 15mL of raw 5X-Amdex-CdS sol were purified on G-25 Sephadex, 0.300mL of 10mg/mL sulfo-SMCC solution were used for activation, and the two brightest fractions (22 and 23) of sulfo-SMCC-5X-Amdex-CdS were pooled and mixed with 17.000mg (5.229mL) of IT-T4 in Run 9. Run 10 was similar to Run 9 except 0.400mL of 10mg/mL sulfo-SMCC solution was used and the four brightest fractions (21, 22, 23, and 24) of sulfo-SMCC-5X-Amdex-CdS were pooled and mixed with 17.900mg (5.000mL) of IT-T4. Traces of the UV monitor-recorder for fractions collected from the Bio-Gel A-5m column for Runs 7, 9, and 10 are shown in Fig. 14, together with SDS-PAGE results for specified, pooled fractions from each run.

Using the same level of activation of 5X-Amdex with sulfo-SMCC as in previous conjugations of 5X-Amdex with CD3 antibody [US Patent 5,527,713;US Patent 5,658,741] or with phycoerythrin and monoclonal antibody would require 0.450mL of 10mg/mL sulfo-SMCC solution or 0.010 mmol sulfo-SMCC (MW, 436.37g/mol) per 25mg 5X-Amdex. For a two diaminopropane group repeating unit of 4 x 355.3 Da and 2 mol of primary amine per repeating unit, there would be 0.035 mmol of amine groups per 25mg 5X-Amdex. Thus, the amine-to-sulfo-SMCC molar ratio was 3.5, providing enough sulfo-SMCC to activate about 30% of the primary amine groups in 5X-Amdex. In the present runs with 5X-Amdex-CdS conjugates best results were obtained at about 10-fold lower activation levels where the amine-to-sulfo-SMCC molar ratio was about 30 to 50, giving enough sulfo-SMCC to activate 2-3% of the primary amine groups in 5X-Amdex. Higher sulfo-SMCC amounts between 0.400 and 0.900mL of 10mg/mL sulfo-SMCC solution in the above procedure reduced the

luminescence intensity of CdS nanoparticles by about 5-10-fold to very low levels. Higher IT-T4 amounts between 18 and 42mg during conjugation simply gave more excess antibody in fractions 35 to 50 on the Bio-Gel A-5 column [Bio-Rad Laboratories], affording a poorer separation of conjugates from free antibody.

5

Example 9 - Spectral Measurements of Purified 5X-Amdex-CdS and T4 Antibody-5X-Amdex-CdS Conjugates

Fifteen milliliters of raw sol were applied to the top of a G-25 Sephadex column (2.5cm x 48cm) equilibrated with 1xPBS. Fractions of 120 drops or about 3.6mL were collected. A narrow first band at about fraction no. 21 and a broader second band between fraction nos. 23 and 25 were observed with an A₂₈₀ monitor, as well as a hand-held lamp (366nm, Model UVL-21 Blak-Ray lamp, Ultra-Violet Products, Inc., San Gabriel, CA) to observe luminescence emission on the column. Absorption spectra, luminescence emission spectra with 360nm excitation, and QELS were measured for relevant fractions and the results are summarized in Table 6.

15

Table 6. Data for fractions of raw 5X-Amdex-CdS sol chromatographed on G-25 Sephadex.

Fraction Number	Luminescence intensity, arbitrary units	90° light scattering intensity, counts/sec x 10 ⁴	Mean diameter, nm
20	214	2.34	4.5(3)
21	255	6.91	4.4(3)
22	586	8.79	4.7(3)
23	980	8.35	7.0(3)
24	910	6.33	9.2(3)
25	840	4.29	10.4(2)

The maximum absorption at about 365nm was observed for fraction no. 21; however, maximum luminescence emission intensity was detected in three fractions, nos. 23-25, while maximum 90° light scattering occurred for fraction nos. 22 and 23. The T4-5X-Amdex-CdS conjugates showed an additional protein absorption band centered at 280nm, as seen in Fig. 15 for run 7 samples. Further, the emission spectra of several runs of T4-5X-Amdex-CdS conjugates are compared with the same fluorimeter settings (1.5nm excitation and emission slits) in Fig. 16. The highest of these emission band intensities at 500nm was about 4- to 5-fold lower than the same band intensity for the parent 5X-Amdex-CdS complex, and for the

25

fluorescent, organic dye, fura-2, pentapotassium salt (Molecular Probes, Inc.) at a concentration of 5 μ M in 1xPBS buffer solution. QELS results for Run 7 conjugates, fractions 22-30 and fractions 31-40, were 32.7nm and 24.3nm, respectively, for the mean diameter from three measurements per sample. Using an average diameter of 9nm for the 5X-Amdex-CdS raw sol fractions that were pooled, average thicknesses for the layer of T4 monoclonal antibody (IgG1 class) around the 5X-Amdex-CdS particles were calculated as 11.8 and 7.6nm, respectively.

Example 10 - Biological Activity of T4-5X-Amdex-CdS Conjugates

Whole blood control (IMMUNO-TROL™, Beckman Coulter Inc., Miami, Florida) was delivered in 100 μ L volumes into 12 x 75 mm tubes. T4-5X-Amdex-CdS conjugate suspensions were added to respective tubes. Samples were processed with either digitonin or saponin (Sigma) in 1xPBS to provide a non-acid-lyse of red blood cells. Titers (10 to 50 μ L) of T4-5X-Amdex-CdS conjugate were run to establish saturation of lymphocyte CD4 receptor sites. 500 μ L of a 500 μ g/mL digitonin or 0.1% saponin solution in 1xPBS was added, mixed, and incubated with sample mixtures in the tubes for 1 or 2 minutes, respectively. Cells were washed by adding 2 mL of PBSF (1xPBS with 0.01% sodium azide and 2.5% fetal bovine serum) to the tubes, centrifuged at 200 g for 5 minutes, supernatant solutions discarded, and 1 mL of PBSF added. Each run included a non-treated (no T4-5X-Amdex-CdS) control to establish fluorescence background for a negative gating region and a T4-5X-Amdex-CdS treated control to identify T4-5X-Amdex-CdS conjugate binding. The treated control was obtained by further incubating the mixtures in tubes with sheep anti-mouse antibody-phycoerythrin, SAM-PE (product of Silenus Laboratories, Hawthorne, Australia), for 15 min to identify the percent of cells with bound T4-5X-Amdex-CdS conjugate. The processed IMMUNO-TROL cells were analyzed on a COULTER® EPICS® Elite ESP™ flow cytometer. The cell suspensions were excited using an argon ion laser tuned to 488.0nm with 100 mW output laser power. Fluorescence emission from PE or FITC was collected through an interference filter using a photomultiplier. Ten thousand events were collected for each sample after discriminating out electronic noise and debris. All sample data were collected and stored in list mode for further data reduction.

Histograms obtained from flow cytometry of samples prepared as described for whole blood control mixed with T4-5X-Amdex-CdS conjugate/SAM-PE, and lysed with either digitonin or saponin are shown in Fig. 17, top half. Histograms of the same whole blood control treated with the direct marker, T4-FITC, only instead of T4-5X-Amdex-

CdS/SAM-PE are shown in the bottom half of Fig. 17. Similar results for the percent T4 positive lymphocytes confirm that purified T4-5X-Amdex-CdS conjugate is labeling the same receptor sites on lymphocytes as the reference marker, T4-FITC. Thus, a model for the formation of the T4-5X-Amdex-CdS conjugate and its binding to T4+ lymphocytes is displayed in Fig. 18.

- The flow cytometry results show that it may not be possible to use all cadmium chalcogenide nanoparticles equally well as direct luminescence labels; rather, only CdSe and CdTe particles, which show band gap absorption band maxima in the visible and near-infrared spectral regions, have the potential to be readily used as direct markers.
- 10 Luminescence emission intensities of CdS nanoparticles of 2-5nm diameter attached to aminodextran of MW range, 30 to 75 kDa, and excited with near-UV laser lines were not high enough to be able to discriminate them from the high fluorescence background from white blood cells. Larger CdS nanoparticles of 5-10nm diameter might be useful since their excitation bands are shifted into the visible region between 400 and 500nm, wherein
- 15 background luminescence intensities from white blood cells are not as high. Also, larger 5X-aminodextrans in the range 100 to 500 kDa have the potential to accommodate more CdS nanoparticles per molecule, and thus enhance luminescence intensities of these markers.

WHAT IS CLAIMED IS:

1. A semiconductor nanoparticle for the analysis of fluid samples comprising:
 - a) a water soluble amino derivative of a polysaccharide having an average
5 molecular weight from approximately 3,000 to 3,000,000 Da, a size in diameter of less than approximately 150 nanometers, and a degree of substitution of total number of primary and secondary amino groups in the polysaccharide molecule ranging from 1/150 to 4/1; and
 - b) at least one nanoparticle of the formula:
$$(X Y)_n$$

10 wherein X is selected from the group comprising Cd^{2+} , Hg^{2+} , and Zn^{2+} and combinations thereof; and Y is selected from the group comprising S^{2-} , Se^{2-} and Te^{2-} and combinations thereof; and $n =$ approximately 50 to 1000, wherein said nanoparticle is linked to said aminopolysaccharide.
- 15 2. The semiconductor nanoparticle of claim 1 having the size in diameter of approximately 1 to 10 nanometers.
3. The semiconductor nanoparticle of claim 1, wherein the polysaccharide is dextran.
20
4. The semiconductor nanoparticle according to claim 3, wherein the dextran is selected from the group consisting of 5X-aminodextran and 1X-aminodextran.
5. The semiconductor nanoparticle according to claim 3, wherein the dextran is
25 substituted with 1,3-diaminopropane.
6. The semiconductor nanoparticle according to claim 1, wherein at least one nanoparticle is CdS.
- 30 7. The semiconductor nanoparticle according to claim 1, wherein the degree of substitution is in the range of 1/25 to 2/5.
8. The semiconductor nanoparticle according to claim 1, wherein the amino derivative of a polysaccharide has a molecular weight of less than 500,000.

9. The semiconductor nanoparticle according to claim 1, wherein 1 to 3000 nanoparticles are covalently bound to said amino derivative of the polysaccharide.

5 10. A method of making a semiconductor nanoparticle comprising the step of:

reacting a) an amino derivative of a polysaccharide having a molecular weight from approximately 3,000 to 3,000,000 Da with b) a Periodic Table Group IIB water soluble salt and with c) a Group VIA salt to form a semiconductor nanoparticle;

10 said amino derivative of a polysaccharide having a diameter of less than approximately 150 nanometers and a degree of substitution of total number of primary and secondary amino groups in the polysaccharide molecule ranging from 1/150 to 4/1; and said Group IIB salt having a cation selected from the group consisting of Cd^{2+} , Hg^{2+} , and Zn^{2+} and combinations thereof; and an anion selected from the group consisting of Cl^- , ClO_4^- , NO_3^- and SO_4^{2-} ;

15 said Group VIA water soluble salt having a cation selected from the group consisting of Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Sr^{2+} , and Ba^{2+} ; and an anion selected from the group consisting of S^{2-} , Se^{2-} and Te^{2-} and combinations thereof; such that the anion selected for the Group IIB salt does not precipitate with the cation of the Group VIA salt,

20 wherein the polysaccharide contains a reducing sugar which retards photo-oxidation of the nanoparticle contained in the formed semiconductor nanoparticle.

11. The method of claim 10, wherein said Periodic Table Group IIB water soluble salt is mixed with said amino derivative of a polysaccharide to form a first product and the first product is reacted with said Group VIA salt to form the semiconductor nanoparticle.

25

12. The method of claim 10, wherein said Group VIA salt is mixed with said amino derivative of a polysaccharide to form a first product and the first product is reacted with said Periodic Table Group IIB water soluble salt to form the semiconductor nanoparticle.

30 13. The method of claim 10, wherein said Group VIA salt is mixed with said amino derivative of a polysaccharide to form a first product and said Periodic Table Group IIB water soluble salt is mixed with said amino derivative of a polysaccharide to form a second product and said first product is reacted with said second product to form the semiconductor nanoparticle.

14. The method of claim 13, wherein said first product and second product are reacted in the presence of additional amino derivative of a polysaccharide.

5 15. The method of claim 10, wherein said Periodic Table Group IIB water soluble salt and said Group VIA salt are concurrently mixed with said amino derivative of a polysaccharide to form the semiconductor nanoparticle.

10 16. The method according to claim 10, wherein the Group IIB salt cation is Cd^{2+} .

17. The method according to claim 10, wherein the Group VIA salt anion is S^{2-} .

18. The method according to claim 10, wherein the first salt is at a higher concentration than the second salt.

15 19. The method according to claim 10, wherein the amino derivative of a polysaccharide is present in an amount of about 0.2 to 20 mg/ml.

20 20. The method according to claim 10, wherein the reaction occurs at a pH between about 9 to about 12.

21. A semiconductor nanoparticle prepared according to the method of claim 10.

25 22. A ligand-semiconductor nanoparticle comprising a ligand having conjugated thereto at least one semiconductor nanoparticle, wherein said semiconductor nanoparticle comprises:

30 (a) an amino derivative of a polysaccharide having a molecular weight from approximately 3,000 to 3,000,000 Da, a size in diameter of less than approximately 150 nanometers, and a degree of substitution of total number of primary and secondary amino groups in the polysaccharide molecule ranging from 1/150 to 4/1; and

b) at least one nanoparticle of the formula:



wherein X is selected from the group comprising Cd^{2+} , Hg^{2+} , and Zn^{2+} and combinations thereof; and Y is selected from the group comprising S^{2-} , Se^{2-} and Te^{2-} and combinations thereof; and $n =$ approximately 50 to 1000, wherein said nanoparticle is linked to said amino derivative polysaccharide.

23. The ligand-semiconductor nanoparticle according to claim 22, wherein said semiconductor nanoparticle comprises aminodextran-CdS.

24. The ligand-semiconductor nanoparticle according to claim 22, wherein the ratio of ligand to semiconductor nanoparticles is in the range of about 1:1 to about 1:5.

25. The ligand-semiconductor nanoparticle according to claim 22, wherein said ligand is an antibody or a functional fragment thereof.

26. The ligand-semiconductor nanoparticle according to claim 22, wherein said ligand is an anti-CD4 antibody.

27. A method of preparing a ligand-semiconductor nanoparticle comprising the steps of:

a) forming a semiconductor nanoparticle by reacting:

(i) an amino derivative of a polysaccharide having a molecular weight from approximately 3,000 to 500,000 Da, a diameter of less than approximately 50 nanometers and a degree of substitution of total number of primary and secondary amino groups in the polysaccharide molecule ranging from 1/150 to 4/1;

(ii) a water soluble first salt, said first salt having a cation selected from the group consisting of Cd^{2+} , Hg^{2+} , and Zn^{2+} and combinations thereof; and an anion selected from the group consisting of Cl^- , ClO_4^- , NO_3^- and SO_4^{2-} ; and

(iii) a water soluble second salt, said second salt having a cation selected from the group consisting of Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Sr^{2+} , and Ba^{2+} ; and an anion selected from the group consisting of S^{2-} , Se^{2-} and Te^{2-} and combinations thereof; such that the anion selected for the first salt does not precipitate with the cation of the second;

b) purifying the dispersion comprising the polysaccharide semiconductor nanoparticle to remove excess unreacted reagents;

c) activating and purifying the semiconductor nanoparticle;

d) activating and purifying the selected ligand; and

10 e) mixing the activated and purified ligand and the activated and purified semiconductor nanoparticle, thereby permitting formation of the ligand-semiconductor nanoparticle.

28. A method of detecting a target in a biological sample comprising the steps of:

15 (a) contacting a biological sample suspecting of containing a target for a selected ligand with a ligand-semiconductor nanoparticle to form a bound ligand-semiconductor nanoparticle-biological sample, said ligand-semiconductor nanoparticle comprising the selected ligand having conjugated thereto at least one semiconductor nanoparticle, wherein said semiconductor nanoparticle comprises:

20 (i) an amino derivative of a polysaccharide having a molecular weight from approximately 3,000 to 3,000,000 Da, a size in diameter of less than approximately 150 nanometers, and a degree of substitution of total number of primary and secondary amino groups in the polysaccharide molecule ranging from 1/150 to 4/1; and

ii) at least one nanoparticle of the formula:

25 (X Y)_n

wherein X is selected from the group comprising Cd^{2+} , Hg^{2+} , and Zn^{2+} and combinations thereof; and Y is selected from the group comprising S^{2-} , Se^{2-} and Te^{2-} and combinations thereof; and n = approximately 50 to 1000, wherein said nanoparticle is linked to said aminopolysaccharide;

30 (b) exciting said bound semiconductor nanoparticle-biological sample with
infrared to ultraviolet light to cause it to luminesce; and

(c) detecting the luminescence signal, thereby detecting the presence of the target for a selected ligand in the biological sample.

29. The method according to claim 28, wherein the luminescent signal is measured by flow cytometric analysis.
30. The method according to claim 28, wherein the biological sample comprises
5 white blood cells.
31. The method according to Claim 28, wherein the ligand is an antibody or a functional fragment thereof.
- 10 32. The method according to Claim 31, wherein the ligand is an anti-CD4 antibody.

1/18




FIG. 1

2/18




FIG. 2

3/18




FIG. 3

4/18




FIG. 4

5/18




FIG. 5

6/18




FIG. 6

7/18




FIG. 7

8/18




FIG. 8

9/18




FIG. 9

10/18




FIG. 10

11/18




FIG. 11

12/18




FIG. 12

13/18




FIG. 13

14/18




FIG. 14

15/18




FIG. 15

16/18




FIG. 16

17/18

Nanoparticles-CD4/SAM-PE




FIG. 17




FIG. 18

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/06864

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/58 G01N33/533 G01N33/543

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CHAN WCW ET AL: "Quantum Dot bioconjugates for ultrasensitive nonisotopic detection" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 281, no. 281, 25 September 1998 (1998-09-25), pages 2016-2018-2018, XP002125871 ISSN: 0036-8075 cited in the application the whole document</p> <p style="text-align: center;">--- -/--</p>	1-32



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 August 2000

Date of mailing of the international search report

11/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pellegrini, P

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/06864

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BRUCHEZ M JR ET AL: "Semiconductor nanocrystals as fluorescent biological labels" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 281, no. 281, 25 September 1998 (1998-09-25), pages 2013-2016-2016, XP002125872 ISSN: 0036-8075 cited in the application the whole document	1-32
Y	WO 94 09368 A (COULTER CORP) 28 April 1994 (1994-04-28) abstract claims	1-32
Y	US 5 248 772 A (BURSHTEYN ALEXANDER ET AL) 28 September 1993 (1993-09-28) cited in the application abstract claims	1-32
Y	SMITH C.U. ET AL.: "Detection of low-density cell surface markers using novel amplified fluorochrome-conjugated antibodies" CYTOMETRY, vol. Supplement 9, 1998, pages 56-57, XP000933826 abstract	1-32

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/06864

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
W0 9409368 A	28-04-1994	US 5466609 A	14-11-1995
		AU 5360394 A	09-05-1994
		CA 2146964 A	28-04-1994
		EP 0665955 A	09-08-1995
		JP 8502443 T	19-03-1996
		US 5639620 A	17-06-1997
		US 5776706 A	07-07-1998
US 5248772 A	28-09-1993	US 5707877 A	13-01-1998
		AU 3608993 A	01-09-1993
		CA 2128230 A,C	05-08-1993
		CN 1074844 A	04-08-1993
		EP 0625993 A	30-11-1994
		IL 104455 A	18-06-1996
		JP 7504843 T	01-06-1995
		MX 9300391 A	01-07-1993
		NZ 245701 A	28-03-1995
		WO 9315117 A	05-08-1993
		US 5552086 A	03-09-1996
		ZA 9300525 A	25-07-1994

专利名称(译)	用于分析血细胞群的新型半导体纳米颗粒		
公开(公告)号	EP1166120A1	公开(公告)日	2002-01-02
申请号	EP2000917985	申请日	2000-03-15
申请(专利权)人(译)	库尔特INTERNATIONAL CORP.		
当前申请(专利权)人(译)	库尔特INTERNATIONAL CORP.		
[标]发明人	SIIMAN OLAVI MATIJEVIC EGON SONDI IVAN		
发明人	SIIMAN, OLAVI MATIJEVIC, EGON SONDI, IVAN		
IPC分类号	B01J19/00 G01N21/78 G01N33/483 G01N33/53 G01N33/532 G01N33/548 G01N33/58 G01N33/533 G01N33/543		
CPC分类号	B82Y15/00 G01N33/588 Y10T428/2982 Y10T428/2991		
优先权	09/281512 1999-03-30 US		
其他公开文献	EP1166120B1		
外部链接	Espacenet		

摘要(译)

描述了用于分析生物样品的半导体纳米颗粒。该半导体纳米颗粒由氨基葡聚糖组成，所述氨基葡聚糖与至少一种式 (XY)_n 的纳米颗粒结合，其中X选自Cd²⁺、Hg²⁺和Zn²⁺以及其组合；Y选自S²⁻、Se²⁻和Te²⁻及其组合；还提供了制备这些半导体纳米颗粒的方法和制备由与配体连接的这些半导体纳米颗粒组成的缀合物的方法。还描述了在多种生物测定中缀合物的用途。